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ABSTRACT 
Gregory Allen Payne 
 
CONTRIBUTION OF PERIVASCULAR ADIPOSE TISSUE 
TO CORONARY VASCULAR DYSFUNCTION  
 
The epidemic of obesity and associated cardiovascular complications continues 
to grow at an alarming rate. Currently, obesity is thought to initiate a state of chronic 
inflammation, which if unresolved potentially causes cardiovascular dysfunction and 
disease. Although poorly understood, release of inflammatory mediators and other 
cytokines from adipose tissue (adipocytokines) has been proposed to be the molecular 
link between obesity and coronary artery disease. Furthermore, the anatomic location of 
adipose has been increasingly recognized as a potential contributor to vascular disease. 
Importantly, the development of coronary atherosclerosis, a key component of heart 
disease, is typically found in segments of coronary arteries surrounded by perivascular 
adipose tissue. Accordingly, the goal of this project was to determine how perivascular 
adipose tissue affects coronary artery function and elucidate the critical mechanisms 
involved. Initial studies assessing arterial function were conducted with and without 
perivascular adipose tissue. Preliminary results demonstrated that factors released by 
perivascular adipose tissue effectively impaired coronary endothelial function both in 
vitro and in vivo. This observation was determined to be caused by direct inhibition of 
nitric oxide synthase (NOS), a critical enzyme for the production nitric oxide. Attenuation 
of endothelium-dependent vasodilation was independent of changes in superoxide 
production, smooth muscle response, or peroxide-mediated vasodilation. Additional 
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studies revealed that perivascular adipose-induced impairment of NOS was due to 
increased inhibitory regulation by the β isoform of protein kinase C (PKC-β). Specifically, 
perivascular adipose-derived factors caused site specific phosphorylation of nitric oxide 
synthase at Thr-495. Additional experiments investigated how perivascular adipose-
derived factors contributed to coronary artery disease in an animal model of obesity. 
Results from these studies indicated that perivascular adipose-derived leptin markedly 
exacerbated underlying endothelial dysfunction, and significantly contributed to coronary 
endothelial dysfunction through a PKC-β dependent mechanism. Findings from this 
project confirm epicardial perivascular adipose tissue as a local source of harmful 
adipocytokines. In addition, perivascular adipose-derived leptin was demonstrated to be 
a critical mediator of coronary vascular dysfunction in obesity. Together, the results 
strongly suggest that perivascular adipose tissue is a key contributor to coronary artery 
disease in obesity.   
Johnathan D. Tune, Ph.D., Chair 
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Chapter 1  
 
The Epidemic of Obesity and Metabolic Syndrome  
Within the United States, the incidence of obesity has undoubtedly reached 
epidemic proportion. Since 1980, obesity rates among adults within the United States 
have more than doubled, signaling the rapid development of a health crisis for all ethnic 
and socioeconomic groups throughout the nation. Sadly, while our acknowledgement 
and appreciation for the severity of this problem has increased, little evidence suggests 
that current efforts have substantially deterred weight gain across the country. Defined 
as a body max index (BMI) of ≥ 30 kg/m2, approximately 33% of adult men and 35% of 
adult women within the United States were considered obese in 20061. As of 2009, still 
more than a third of the population (or 72 million individuals) is definably obese, with 
many more considered overweight2.  
Perhaps even more concerning is the dramatic increase in childhood obesity. In 
the United States, more than 16% of children and adolescents are obese, representing a 
threefold increase over the past three decades2.  Lastly, these detrimental dietary and 
behavioral practices have managed to extend far beyond our domestic borders. In 
particular, recent estimates indicate that there are approximately 1 billion individuals 
worldwide who are either overweight or obese (BMI ≥ 25 kg/m2)3. Together, these 
statistics exemplify the dire situation confronting both adults and children worldwide. 
While the growing prevalence of obesity alone is problematic, even more 
troubling is the expected increase in obesity-associated cardiovascular disease. Since 
the landmark Framingham Heart Study first began to identify key factors contributing to 
cardiovascular disease, subsequent investigations have further demonstrated obesity-
induced increases in the incidence of coronary atherosclerotic disease, 
cardiomyopathies, myocardial infarction, sudden death, congestive heart failure, and 
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stroke4-10. For example, men with a BMI of ≥ 30 kg/m2 are at a tremendous risk of death 
from cardiovascular disease (relative risk of 2.90)11.  Furthermore, individuals who are 
either overweight or obese are at greater risk for a number of harmful clinical conditions 
(Figure 1-1)12. Importantly, cardiovascular pathologies have long been among the 
leading causes of death nationwide. Hence, the relatively sharp increase in obesity 
promises to further exacerbate the incidence and mortality of these deadly conditions, 
and apply additional strain on our healthcare system. 
 
Figure 1-1  Health risks associated with elevated body mass index. Relative risk of 
death from cardiovascular disease, cancer, and other causes among men and women 
are shown. Note the sharp increase in cardiovascular risk associated with body mass 
indices greater than approximately 2511.  
 Current hypotheses, however, speculate that simple measurement of BMI may 
not be sufficient to provide a detailed cardiovascular risk assessment for individual 
patients13, 14. Specifically, results from the International Day for the Evaluation of 
Abdominal Obesity (IDEA) confirmed that waist circumference (as opposed to BMI) is a 
stronger indicator of cardiovascular disease and type II diabetes in normal, overweight, 
and obese patients14, 15. These results suggest that general weight gain alone is not 
solely responsible for disease, and that abdominal (or visceral) adiposity has particularly 
deleterious effects on cardiovascular health. This conclusion has subsequently been 
supported by several investigations reporting differing risks associated with abdominal 
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versus peripheral obesity16-18. Hence, while increases in total body weight may serve as 
a convenient indicator of cardiovascular risk, other mechanisms (either dependent or 
independent of body weight) are clearly contributing to the progression of obesity-
induced cardiovascular disease.     
With these limitations of BMI measurements in mind, investigators have sought 
to define a set of obese risk factors better associated with cardiovascular disease. 
Consequently, research throughout the past decades has accumulated evidence of a 
clustering of cardiovascular risk factors referred to as ―metabolic syndrome‖ (MetS)15, 19-
21. Patients with MetS classically display a constellation of symptoms including 
hypertension, insulin resistance, truncal obesity and dyslipidemia22. Clinically, patients 
displaying an elevated waist circumference (≥ 40 for men, 35 for women), elevated 
triglycerides (≥ 150 mg/dL), reduced HDL cholesterol (< 40 mg/dL for men, 50 for 
women), elevated blood pressure (> 130/85 mmHg), and elevated fasting glucose (≥ 110 
mg/dL) are considered to suffer from MetS23. Estimates suggest that more than 30 % of 
the adult population within the United States exhibits characteristics of this pre-diabetic, 
metabolic disorder23-25. Importantly, earlier investigations have established that each 
component of MetS is an independent risk factor for cardiovascular disease5, and that 
patients are subject to a 61% increased risk of cardiovascular events4. Hence, a large 
portion of the population may be living at increased risk of cardiovascular disease before 
any clinical signs (i.e. morbid obesity or type II diabetes mellitus) are readily apparent.       
Despite this growing epidemic, the pathophysiologic mechanisms underlying the 
link between obesity and cardiovascular disease remain poorly understood. 
Consequently, the long-term goal of our research is to delineate the central mechanisms 
of obesity-induced coronary vascular disease with the intention of identifying novel 
therapeutic targets to reduce the incidence of cardiovascular complications in obese 
patients. The specific focus of this work was to better understand how adipose tissue, an 
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active endocrine organ, directly affects coronary vascular function under both lean and 
obese conditions. In particular, dysfunction of normal coronary vascular function is 
suggested to be the initiating event in progression of several weight related 
cardiomyopathies (i.e. coronary artery disease and myocardial infarction)26.  The central 
premise of the following studies is that local perivascular adipose tissue surrounding the 
large conduit vessels of the heart is a significant regulator of coronary vascular function 
and contributor to the development of coronary artery disease in obese patients with the 
MetS.  
Adipose Tissue, Inflammation, and Cardiovascular Disease 
 Adipose tissue has become the subject of considerable research interest in 
recent years. Results throughout the past decade have prompted many investigators to 
recognize the important relationships among adipose tissue, obesity, chronic 
inflammation, and cardiovascular disease.   For many years, adipose tissue was thought 
to be a relatively inactive signaling organ. While brown adipose tissue has long been 
associated with thermogenesis and body temperature regulation in newborn infants, the 
more abundant white adipose tissue was thought to exclusively function as an energy 
storage depot for fatty acids27, 28. In the late 1980’s and early 1990’s, however, it was 
discovered that adipocytes secrete two signaling proteins associated with inflammation. 
Namely, the complement-related factor adipsin29 and the pro-inflammatory cytokine 
tumor necrosis factor α (TNF-α)30 were recognized to be produced by adipose tissue. 
Together, these initial discoveries challenged long standing assumptions about the 
physiologic nature of adipose tissue.  
The critical change in perspective on the physiological role of adipose tissue 
occurred with the identification of the adipose-derived hormone leptin31. Subsequent 
investigations demonstrated that leptin is associated with the regulation of energy 
balance through endocrine signaling to the hypothalamus32-34. Importantly, investigators 
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have more recently documented that leptin either directly contributes, or is associated 
with several complications of obesity35. These include coronary endothelial dysfunction36, 
coronary heart disease37, and hypertension38-40. These leptin-associated pathologies are 
hallmarks of the MetS, and therefore provide evidence of a molecular link between 
obesity and cardiovascular disease. Together, the discovery of adipose-derived adipsin, 
TNF-α, and leptin serve as the foundation for the current theory of adipose tissue as an 
active endocrine, paracrine, and inflammatory organ41. 
Several investigations have subsequently identified numerous agents produced 
either by adipocytes or within adipose tissue (Figure 1-2). Many of these adipose-
derived cytokines (or adipokines) have been shown to influence a wide spectrum of 
hemodynamic, metabolic, and immunologic factors. These include changes in insulin 
sensitivity (i.e. adiponectin and resistin), inflammation (i.e. IL-8 and monocyte 
chemotactic protein 1), vascular reactivity (i.e. leptin, resistin, TNF-α, adiponectin), and 
coagulation (i.e. plasminogen activator inhibitor 1)36, 41-45. The widespread and 
sometimes detrimental activity of these signaling molecules has resulted in the current 
―adipokine hypothesis‖ linking obesity and cardiovascular disease. To date, there are 
well over 50 adipokines that have been identified with more undoubtedly to follow. Table 
1-1 summarizes a few of these adipokines that are proposed to be linked with obesity, 
MetS, and cardiovascular disease. 
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Table 1-1 Perivascular adipose tissue expression and vascular effect of keyadipokines 
associated with cardiovascular disease. 
  
PROPOSED 
PHYSIOLOGIC 
FUNCTION 
 
PROPOSED 
DISEASE 
ASSOCIATIONS 
 
EFFECT ON 
VASCULAR  
REACTIVITY 
 
EPICARDIAL 
ADIPOSE TISSUE 
EXPRESSION 
 
CITATIONS 
Leptin Energy status 
messenger 
 
Regulator of 
SNS to control 
energy 
expenditure 
 
Short-term 
adapter during 
starvation 
Obesity 
CAD 
Atherosclerosis 
HTN 
DM Type II 
Hepatic Disease 
Endothelial 
Dysfunction 
 
Oxidatice 
stress 
 
Pro- 
thrombotic 
 
VSMC 
migration 
and 
proliferation 
Markedly elevated 
epicardial adipose 
expression  in 
comparison to omental 
adipose form obese 
patients with CAD (2.5 
fold increase) 
34, 46-49 
Resistin Questionable 
link between 
obesity and DM 
Type II 
 
Pro-
inflammatory 
Insulin 
resistance 
CAD 
Endothelial 
Dysfunction 
 
Endothelin-1 
release  
 
Increased 
VCAM-1 
 
 
Elevated with obesity. 
Epicardial expression 
similar to omental 
adipose from obese 
patients with CAD 
43, 48-50 
PAI-1 Inhibits 
plasminogen 
activators and 
fibrinolysis 
 
Pro-
inflammatory 
 
Promote 
adipose 
development 
Obesity 
DM Type II 
Chronic 
inflammation 
 
Correlated 
with impaired 
vascular 
reactivity in 
the setting of 
MetS 
Markedly elevated 
epicardial adipose 
expression  in 
comparison to omental 
adipose form obese 
patients with CAD (2.5 
fold increase) 
49, 51, 52 
Adiponectin Insulin-
sensitizer 
 
Anti-
inflammatory 
 
Fatty acid 
oxidation and 
lipid 
metabolism 
Obesity 
CVD 
CAD 
Insulin 
resistance DM 
Type II 
Dyslipidemia 
 
 
Increased 
CFR 
 
Endothelial 
improvement 
Reduced in all adipose 
tissues from obese 
patients with CAD, but 
significantly greater 
reduction observed in 
epicardial adipose (2 
fold decrease).  
42, 47, 48, 
53, 54 
MCP-1 
 
 
Chemokine 
 
Monocyte 
trafficking 
 
Inflammation 
Obseity 
Atherosclerosis 
CAD 
CVD 
 
Thought to 
propagate 
neointimal 
thickening 
Elevated epicardial 
adipose expression, 
but significantly less 
than omental adipose 
expression.  
 
44, 55, 56 
7 
 
IL-6 Acute-phase 
inflammatory 
reaction 
 
Anti-
inflammatory 
 
Lipolysis 
 
Increase CNS 
activity 
Insulin 
resistance 
DM Type II 
Obesity 
Cachexia 
CVD 
No known 
direct effect, 
but 
associated 
with: 
 
ROS 
 
Endothelial 
Dysfunction 
Markedly elevated 
epicardial adipose 
expression  in 
comparison to omental 
adipose form obese 
patients with CAD (9.5 
fold increase) 
44, 47, 49 
TNF-α Pro-
inflammatory 
cytokine 
Obesity 
Inflammation 
Auto-immunity 
Insulin 
Resistance 
DM 
CVD 
CAD 
ROS 
 
Endothelial 
Dysfunction 
Elevated with obesity. 
Epicardial expression 
similar to omental 
adipose from obese 
patients with CAD 
44, 45, 57 
CAD- coronary artery disease; CVD-cardiovascular disease; HTN-hypertension; SNS-
sympathetic nervous system; CNS-central nervous system; DM-diabetes mellitus; CFR-
coronary flow reserve; ROS-reactive oxygen species 
 
Notably, many adipokines have been either directly or indirectly associated with 
inflammation41, 44, 58. It is therefore not surprising that obese patients have elevated 
inflammatory markers, and display a phenotype characteristic of chronic inflammation59. 
In fact, obesity is strongly associated with elevated C-reactive protein (CRP), TNF-α, IL-
6, and cellular adhesion molecules (CAMs)60. Importantly, these inflammatory proteins 
have each been associated with increased vascular risk and cardiovascular disease61, 62. 
The expansion and growth of adipose depots during obesity is further linked with 
inflammation due to increased monocyte infiltration and activation within adipose 
tissue63. In the setting of obesity, adipocytes therefore provide a wealth of pro-
inflammatory factors, while adipose tissue in general offers a supportive environment for 
inflammatory cells to mount an immune response and further propagate chronic 
inflammation59. Hence, both the inflammatory and endocrine nature of adipose tissue 
provides a potential link between cardiovascular disease and obesity.        
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Figure 1-2  Expression and function of some known adipokines. Adipokines are 
linked to a wide variety hemodynamic, metabolic, and inflammatory factors. Adipose 
tissue is therefore a highly active and regulated secretory organ. Expression of various 
adipokines has been shown to be linked with obesity-related metabolic and vascular 
complications. Adipokines are therefore proposed to be the molecular link between 
obesity and cardiovascular disease. TNF-α (tumor necrosis factor α); IL (Interleukin); 
RANTES (regulated upon activation, normal T cell expressed and secreted); MCP-1 
(monocyte chemotactic protein 1)44.   
Lastly, it should pointed out that different adipose depots have distinct metabolic 
characteristics, leading to individual differences in the impact of obesity on 
cardiometabolic disease. During obesity, abdominal visceral adipose tissue is suggested 
to confer greater risk of cardiovascular complications in comparison to subcutaneous 
adipose tissue64-66. This is due to a few important anatomic and metabolic factors. By its 
anatomic location, the expanded abdominal visceral adipose depot has easy access to 
the liver via the portal circulation (Figure 1-3) 58, 66. As a result, the liver receives a 
increased amount of free fatty acids (FFA) from visceral adipose tissue, leading to 
increased production of lipoproteins, clotting factors, and systemic inflammatory 
factors67, 68. Likewise, abdominal visceral adipose tissue provides a unique source of 
adipokines that may directly impact vascular disease and atherogenesis. While it is not 
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clear how much abdominal adipose tissue contributes to systemic increases of 
inflammatory markers and harmful adipokines, these findings suggest that the anatomic 
location of adipose tissue is an important determinant of obesity-associated 
cardiovascular disease. Additional studies, however, are needed to further elucidate a 
relationship between anatomic location of adipose tissue and disease.       
In the end, while our understanding of a link between adipose tissue and 
cardiovascular disease remains limited, adipokines appear to hold a critical role in 
disease progression. Notably, the majority of these signaling molecules display altered 
expression patterns in the setting of obesity41, 47, 58, 69. In addition, previous studies also 
suggest that the anatomic location of adipose tissue contributes to cardiovascular 
disease. Future investigations are needed to better delineate clear relationships and 
mechanisms underlying adipokine production, anatomic location, and obesity-associated 
cardiovascular disease.   
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Figure 1-3 Contribution of visceral adipose tissue to obesity-induced vascular 
disease. Adipokines work directly at the vessel wall and through the liver to promote an 
atherogenic environment. Adipokines derived from visceral adipose tissue have favored 
access to the liver through the portal circulation. At the liver, adipose tissue–derived 
factors influence the composition and level of circulating lipoproteins and the levels of 
systemic inflammatory and clotting system components. Adipose tissue–derived factors 
also can directly regulate gene expression and function of endothelial, arterial smooth 
muscle, and macrophage cells in the vessel wall. FFA (free fatty acids); PAI 
(plasminogen activator inhibitor)58.  
Obesity and Coronary Vascular Disease 
 While adipokines have received considerable research interest, investigators 
have also sought to understand the overall (or net result) effect of obesity on coronary 
vascular function. There are many plausible mechanisms by which an increase in 
adipose tissue (or adipokines production) could adversely affect coronary vascular 
function and health. These include changes in blood pressure regulation, glucose 
tolerance, lipid metabolism, and chronic inflammation58. While each of these 
mechanisms are important, emerging evidence suggests that the cornerstone of 
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coronary vascular disease is the initial disruption of normal vascular function. Indeed, 
dysfunctional coronary blood flow regulation has been demonstrated to precede any 
changes in metabolism or inflammation70. Hence, although our understanding of the 
cellular and molecular mechanisms controlling obesity-induced coronary disease is 
limited, considerable evidence suggests that dysfunction of the coronary circulation is a 
primary component of disease progression. 
 The etiology of coronary vascular dysfunction, however, is both multi-factorial 
and heavily dependent on which segment(s) of the vascular tree are affected. In 
particular, unique pathology can occur in the small arterioles (located deep within the 
myocardium) and/or in the much larger conduit arteries (i.e. branches of the right and left 
main coronary arteries). Hence, to better understand how adipokines (and other 
suspected agents) may contribute to vascular disease, it is important to first understand 
how obesity in general affects the coronary circulation. Investigating the effect of obesity 
at the level of both the micro- and macrovasculature, therefore, is critical to fully 
understand the mechanisms underlying obesity-induced coronary disease. 
Microvascular Coronary Disease and Obesity 
Disruption of coronary microvascular function as a consequence of obesity is 
thought to underlie the increased morbidity and mortality to cardiovascular diseases 
commonly observed in obese patients71. Adequate coronary circulation is critical for 
optimal cardiac function. The myocardium has a very limited anaerobic capacity, and is 
highly dependent on a continuous supply of oxygen from the coronary circulation to meet 
metabolic demands72-74. If this need for oxygen is not adequately met, the resulting 
underperfusion/ischemia substantially diminishes cardiac function within seconds75-78. 
For this reason, myocardial oxygen consumption (MVO2) is closely matched with oxygen 
delivery (i.e. coronary blood flow) during normal physiologic conditions. Disruption of this 
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delicate feedback system, as observed in both obesity and MetS79, is therefore 
potentially detrimental to cardiac function and cardiovascular health. 
 Mounting evidence suggests that the ability to match coronary blood flow to 
myocardial oxygen demand is diminished with obesity. While measures of resting 
coronary blood flow from both lean and obese subjects demonstrate little to no 
difference70, 79-84, obese patients display a ―hyperdynamic circulation‖ characterized by 
elevated cardiac output, larger stroke volume, and increased cardiac mass85-88. These 
hyperdynamic changes increase MVO2 by altering the key determinants of myocardial 
metabolism (i.e. heart rate, arterial pressure, ventricular work, and wall stress)79, 83, 89. 
Therefore, despite similar resting blood flow measures, myocardial oxygen demand is 
increased with obesity. Accounting for these differences reveals that obese subjects 
have a depressed cardiac index and reduced contractile performance83, 85, 88, 90    
In contrast to resting coronary blood flow, data from human patients clearly 
demonstrate diminished coronary flow reserve (the difference between maximal and 
baseline coronary blood flow) with obesity and MetS70, 80-82, 84. These findings suggest 
that obese patients have a limited capacity to vasodilate and provide sufficient oxygen 
during situations of increased myocardial metabolic demand. Specifically, results from 
Kiviniemi et. al. demonstrate that waist-to-hip ratio is a negative, independent predictor 
of coronary blood flow reserve in young, healthy men (Figure 1-4)70. Furthermore, the 
onset and severity of microvascular dysfunction appears to parallel the progressive 
increase of truncal fat. The observed reduction in flow reserve could be related to 
impaired vasodilator capacity, enhanced vasoconstrictor responsiveness, and/or 
structural remodeling of the coronary microvasculature91, 92. 
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Figure 1-4  Waist-to-hip ratio is a negative, independent predictor of coronary 
blood flow reserve. The correlation of waist-to-hip ratio with coronary flow velocity 
reserve (cfvr) in young, healthy men is shown. Blood flow velocity was measured by 
transthoracic echocardiography70. 
 To further investigate this observed impairment of coronary blood flow regulation, 
our laboratory explored the control of coronary blood flow in conscious, instrumented 
control and chronically high-fat-fed dogs at rest and during graded treadmill exercise79. 
When fed a high-fat diet, these animals displayed many of the characteristics of MetS 
including obesity, insulin resistance, dyslipidemia, hyperleptinemia, and impaired blood 
pressure regulation79, 89, 93. We documented that the MetS significantly attenuated 
exercise-induced coronary hyperemia. In particular, slopes of coronary blood flow vs. 
MVO2 and coronary conductance vs. MVO2 relationships were significantly depressed in 
obese dogs relative to normal controls (Figure 1-5A). In addition, there was a significant 
parallel downward shift in the relationship between coronary venous PO2 and MVO2 in 
the high-fat-fed dogs (Figure 1-5B), suggesting loss of a tonic vasodilator mechanism 
and/or activation of a tonic vasoconstrictor mechanism73, 74. These data are consistent 
with coronary flow responses to cardiac pacing in obese patients with the MetS80. 
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Figure 1-5  Effects of the MetS on control of coronary blood flow at rest and 
during increases in myocardial metabolism. Data are adapted from Setty et al., 
200379. Coronary blood flow was measured from a flow probe around the left circumflex 
artery; blood was sampled from the aorta and coronary sinus. MVO2 was calculated from 
the arterial-coronary venous O2 difference and coronary flow. A plot of coronary 
conductance vs. MVO2 and demonstrates that the MetS significantly attenuates vascular 
response to increased metabolic demand (A). Coronary blood flow was converted to 
coronary vascular conductance, as dogs fed a high fat diet were hypertensive and thus 
had a greater driving force for flow. This impairment of coronary blood flow control forced 
the myocardium to increase O2 extraction (decrease coronary venous PO2 at a given 
MVO2) to meet the metabolic requirements of the heart (B). 
Together, these findings demonstrate that the MetS impairs the ability of the 
coronary microcirculation to match myocardial oxygen supply with oxygen demand. This 
could be related to a variety of pathophysiological conditions associated with obesity and 
the MetS. These potential conditions include alterations in endothelial-dependent control 
of coronary blood flow, activation of vasoactive neural-hormonal pathways, as well as 
dysfunction of microvascular ion channels (Figure 1-6). Importantly, coronary 
dysfunction in the MetS has been associated with sensitization of vasoconstrictor 
pathways, impaired K+ channel function, and augmented L-type Ca2+ channel activity in 
smooth muscle of resistance arteries71. Hence, dysfunction of the coronary 
microcirculation could result in various cardiomyopathies, and represents one critical 
(and multifaceted) component of obesity-induced vascular disease. The mechanism and 
contribution of each of these conditions to cardiovascular disease is complex (and not 
further discussed within this text); however, it is important to note that the precise cellular 
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and molecular mechanisms underlying these obesity-associated conditions are not 
completely understood.   
 
Figure 1-6  Scheme of mechanisms associated with coronary microvascular 
dysfunction in obesity and MetS. Vasoconstrictor pathways are shown in red while 
vasodilator pathways are depicted in green. The MetS is associated with impaired 
coronary endothelial function, activation of vasoactive neural-hormonal pathways, as 
well as dysfunction of microvascular ion channels.  Ang II (angiotensin II); NE 
(norepinephrine); ECE (endothelin converting enzyme); eNOS (endothelial nitric oxide 
synthase)71.  
Macrovascular Coronary Disease 
In contrast to the coronary microvasculature, the larger epicardial arteries of the 
heart contribute very little to blood flow regulation94-97. In principal, these major coronary 
arteries serve as conduits for arterial blood flow between the ascending aorta and the 
smaller resistance arteries deep within the myocardium. While endothelial dysfunction 
and intensified vasoconstriction appear to be hallmarks of obese coronary circulation, 
these mechanisms may cause dramatically different pathologies in coronary conduit 
vessels as opposed to the microcirculation. In particular, coronary atheroclserosis (or 
coronary artery disease) is the primary obesity-associated pathology observed in large 
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coronary arteries. In addition, more hazardous atherosclerotic lesions typically occur in 
the larger coronary arteries as opposed to distal branches and microvessels98.  
 Research throughout the past decades has intensely sought to understand the 
cellular and molecular mechanisms underlying atherosclerosis. Initially, atherosclerosis 
was viewed as the accumulation of lipids within the arterial wall; however, many 
investigations have demonstrated the disease to be much more complex. In fact, 
coronary artery disease is currently understood to be a highly complex cellular and 
molecular inflammatory response41, 58. For this reason, identifying critical mediators of 
obesity-induced atherosclerosis has proven difficult. 
In the 1970’s, it was proposed that endothelial injury was the initiating event in 
the development of atherosclerosis99. This initial proposal has now developed into the 
―response-to-injury‖ hypothesis of atherosclerosis. This hypothesis states that chronic 
endothelial dysfunction precipitates the cascade of cellular events that result in arterial 
plaque formation (Figure 1-8)100, 101. Specifically, endothelial dysfunction is thought to 
increase platelet and inflammatory cell adhesion along the arterial wall. This results in 
both a pro-inflammatory and pro-coagulant environment at the endothelium. If the 
inflammatory response is not quelled, increased vascular permeability results allowing 
leukocytes to migrate beneath the endothelial layer. In doing so, the inflammatory 
response continues resulting in the activation of vascular smooth muscle cells to 
proliferate and migrate towards the arterial lumen. In the setting of obesity, a vicious 
cycle of inflammation, lipid deposition, and smooth muscle proliferation results in early 
―fatty streaks‖ and atherosclerotic lesions. If unabated, these lesions can progress into 
complicated, stenotic plaques with necrotic cores that are susceptible to rupture100-104. 
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Figure 1-7  Pathogenesis of atherosclerosis. Endothelial dysfunction is proposed to 
be the initiating event in the development of atherosclerosis. STAGE 1: The earliest 
changes that precede the formation of lesions of atherosclerosis take place in the 
endothelium. These changes include increased endothelial permeability to lipoproteins 
and other plasma constituents. This is mediated by altered nitric oxide, prostacyclin, 
platelet-derived growth factor, angiotensin II, and endothelin activity. Up-regulation of 
leukocyte adhesion molecules and endothelial adhesion molecules leads to the 
migration of leukocytes into the artery wall. STAGE 2: Fatty streaks initially consist of 
lipid-laden monocytes and macrophages (foam cells) together with T lymphocytes. Later 
they are joined by various numbers of smooth-muscle cells. The steps involved in this 
stage include smooth-muscle migration, T-cell activation, foam-cell formation, and 
platelet adherence and aggregation. STAGE 3: As fatty streaks progress to intermediate 
and advanced lesions, they tend to form a fibrous cap that walls off the lesion from the 
lumen. This represents a type of healing or fibrous response to the injury. The fibrous 
cap covers a mixture of leukocytes, lipid, and debris, which may form a necrotic core. 
These lesions expand at their shoulders by means of continued leukocyte adhesion and 
entry. The necrotic core represents the results of apoptosis and necrosis, increased 
proteolytic activity, and lipid accumulation. If unabated, atherosclerotic plaques can grow 
large enough to impede blood flow (flow-limiting stenosis) or rupture causing rapid 
thrombosis and occlusion.  Modified from Ross, NEJM, 1999104.   
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The endothelium is therefore a critical regulator of vascular permeability, 
inflammatory cell adhesion, and platelet activation. Thus, endothelial cells provide a 
protective barrier for undisturbed blood flow and inappropriate inflammatory reactions. 
Disruption of this protective barrier, is generally detrimental to normal vascular reactivity, 
homeostasis, and blood flow regulation102, 103. Furthermore, in the setting of high shear 
stress and turbulent blood flow (i.e. large coronary arteries), vessels are particularly 
vulnerable to injury if the vascular endothelium is impaired or dysfunctional98, 105. 
Collectively, the onset of obesity or MetS (i.e. inflammation, hyperlipidemia, 
hyperglycemia, and hypertension) compromises the natural endothelial response to 
blood flow and potentially initiates the development of atherosclerosis, particularly in 
large coronary arteries (Figure 1-7)105, 106. 
 
Figure 1-8 Obesity causes coronary endothelial dysfunction in conduit coronary 
arteries. Left circumflex coronary arteries from normal and high fat fed swine were used 
to test endothelium-dependent and endothelium-independent vascular responses. 
Coronary artery vasorelaxation in response to endothelium-independent stimulus sodium 
nitroprusside (SNP; left) was modestly decreased by high fat feeding. In contrast, 
response to endothelium-dependent stimuli bradykinin (right) was dramatically reduced 
by high fat feeding (*P < 0.001). Modified from Galili O, AJP, 2007106.    
While much is currently known about the development of atherosclerosis, we still 
lack a comprehensive understanding of the relationship between obesity and 
macrovascular disease. In particular, current investigative results have failed to provide 
a stepwise mechanism linking the endocrine nature adipose tissue with coronary heart 
disease. In addition, there is limited evidence explaining why atherosclerosis is primarily 
a macrovascular disease. These observations strongly suggest that additional 
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mechanisms are at work. Despite these knowledge gaps, endothelial dysfunction 
appears to be the pivotal starting point of coronary artery disease.      
Adipokines and Coronary Endothelial Function 
 Although adipokines have been proposed to be the molecular link between 
obesity and cardiovascular disease107, much work is still needed. The versatile activity of 
adipokines and the multifaceted nature of coronary artery disease has made discovering 
specific, disease causing adipokines especially difficult.   Furthermore, it is fair to 
speculate that adipokines do not contribute equally throughout the entire pathogenesis 
of vascular disease. Together, these obstacles have delayed both our scientific and 
clinical understanding of obesity-associated diseases.  
 Despite these difficulties, researchers have attempted to link adipokines with 
various components of cardiovascular disease. Given the suggested importance of the 
endothelium, several studies have linked specific adipokines with endothelial 
dysfunction. In particular, results from our laboratory and others have demonstrated that 
both leptin (Figure 1-9) and resistin (Figure 1-10) impair endothelial function36, 43, 106, 108, 
109. Specifically, we found that concentrations of leptin in the obese range (approximately 
≥ 10 ng/ml) impair acetylcholine-mediated coronary vasodilation in open-chest dogs (in 
vivo) and isolated circumflex coronary artery rings (in vitro)36. Leptin administration alone 
had no effect on coronary vascular tone or hemodynamics. Interestingly, physiologic (~4 
ng/ml) concentrations of leptin had no effect on acetylcholine-mediated coronary artery 
relaxation (Figure 1-9). In this study, leptin concentrations in the obese range did not 
affect endothelium-independent coronary vasodilation to sodium nitroprusside (data not 
shown). Thus, the effect of leptin on coronary vasomotor responses was specific for 
endothelial-mediated dilation in both conduit and resistance coronary arteries, indicating 
direct effects on NO production.    
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Figure 1-9 Leptin induces significant coronary endothelial dysfunction. Leptin 
impairs acetylcholine-mediated coronary artery relaxation of isolated canine coronary 
canine coronary artery rings at a concentration of 10 ng/ml but not 4 ng/ml (A). Leptin 
significantly reduced endothelium-dependent coronary vasodilation to acetylcholine in 
open-chest anesthetized canines (B). Modified from Knudson et al., AJP, 200536. 
 In the same way, Dick et al.43 studied the hemodynamic effects of intracoronary 
administration of resistin both in vivo and in vitro. Intracoronary administration of resistin, 
like leptin, did not significantly affect coronary vasomotor tone or systemic 
hemodynamics. However, resistin did significantly attenuate coronary blood flow 
increases and arterial dilation to bradykinin (but not acetylcholine, Figure 1-10). Thus, 
both resistin and leptin can cause significant endothelial dysfunction when acutely 
administered both in vivo and in vitro36, 43. These findings are important because 
decreased nitric oxide (as well as other endothelium-derived vasodilators) in some 
degree regulate cellular adhesion, vascular permeability, and other precipitating events 
in the initiation of atherosclerosis104.   
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Figure 1-10 Resistin induces significant coronary endothelial dysfunction. Resistin 
significantly attenuated coronary endothelium-dependent vasodilation to bradykinin, but 
not acetylcholine, in open-chest anesthetized dogs (B) and isolated coronary artery rings 
(A). Modified from Dick et al., AJP, 200643.   
 In addition to resistin and leptin, other adipokines have also been linked with 
endothelial dysfunction and cardiovascular disease. Accumulating evidence suggests 
that the inflammatory cytokine TNF-α plays a pivotal role in the disruption of 
macrovascular and microvascular circulation both in vivo and in vitro45, 57. In particular, 
advanced glycation end-products (AGE) / receptor for AGEs (RAGE), lectin-like oxidized 
low-density lipoprotein receptor (LOX)-1, and nuclear factor kappaB (NF-kappaB) activity 
play key roles in increasing TNF-alpha expression57, 110-112. The increase in TNF-alpha 
expression induces the production of reactive oxygen species (ROS), resulting in 
endothelial dysfunction in many pathological conditions.  
Interestingly, adiponectin has been associated with endothelial 
improvement/protection through multiple means, and is significantly decreased during 
obesity42. First, the anti-inflammatory nature of adiponectin may directly attenuate the 
detrimental effects of other adipokines (i.e. leptin, resistin, or TNF-α)42, 48. Second, 
studies by Date et al. and Takano et al. suggest a relationship between adiponectin and 
coronary endothelial response. Results from Date et al. demonstrate an association 
between plasma adiponectin and coronary flow reserve, while Takano et al. showed a 
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negative correlation between adiponectin and coronary endothelial response to 
acetylcholine53, 54.  
Together, these studies suggest that multiple adipokines may regulate coronary 
vasomotor function and the pathogenesis of coronary artery disease42, 46-48, 58. However, 
plasma concentrations of many reported adipokines have not proved to be extremely 
valuable as clinical indicators of cardiometabolic risk. In particular, elevated levels of 
adiponectin have paradoxically been associated with increased risk and mortality to 
coronary artery disease, renal disease, and heart failure113. Similarly, plasma 
concentrations of leptin are only moderately associated with coronary heart disease114. 
Again, these findings suggest that our understanding of obesity-associated 
cardiovascular disease remains limited, and that additional mechanisms are likely 
responsible. 
Perivascular Adipose Tissue and Coronary Artery Disease     
As was previously mentioned, the anatomical distribution of adipose tissue is a 
major determinant of metabolic and cardiovascular diseases. While abdominal adiposity 
has received considerable attention, there is mounting evidence that local visceral 
epicardial adipose tissue may contribute to unfavorable cardiometabolic 
complications115-118. This hypothesis is important because it is among the first to suggest 
an alternative, local pathway in the development of obesity-associated vascular disease. 
Hence, ―local obesity‖ (as opposed to generalized increases in percent body fat) around 
the heart may be an important regulator of vascular function and disease progression. 
Unfortunately, little is currently known about the physiologic and pathophysiologic 
functions of perivascular adipose tissue. 
Perhaps the most noticeable uncertainty regarding the proposed pathologic role 
of perivascular adipose tissue is determining how factors produced within the adventia 
are able to traverse the arterial wall. While experimental evidence remains limited, 
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studies suggest that the coronary vasa vasorum help to traffic harmful adipokines 
between perivascular adipose tissue and the vascular lumen119-121. Above all, results 
from Herrman et al. demonstrated that increased coronary vasa vasorum 
neovascularization preceded overt coronary endothelial dysfunction and disease in 
domestic swine fed a high cholesterol diet (Figure 1-11)120.  These findings suggest an 
―outside-to-inside‖ signaling paradigm that further justifies a pathologic role of 
perivascular adipose tissue118, 122, 123.   
 
Figure 1-11 Increased vasa vasorum density precedes coronary endothelial 
dysfunction in high cholesterol (HC) fed swine. Bottom: a collage of volume-
rendered micro-CT images (scanned in 2-cm increments) adding up to intact left anterior 
descending (LAD) coronary arteries from a high-cholesterol (HC, black bars) and a 
control (N, grey bars) pig. The LADs are subdivided in three equal thirds and vasa 
vasorum parameters are determined and displayed accordingly (here vasa vasorum 
spatial density). In these particular LADs, proximal portions of the LAD show a higher 
spatial vasa vasorum (VV) density than the distal portions (*P < 0.001). Modified from 
Gossl M et al., Atherosclerosis, 2007 119. 
  Initial studies have shown that perivascular adipose tissue significantly 
attenuates contractile responses of rat aorta124-126, rat mesenteric arteries127, 128, and 
human internal thoracic arteries129, 130. In addition, the mechanism of this anti-contractile 
effect is proposed to be the release of undefined transferable factor(s) (i.e. adipocyte-
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derived-relaxing factor) that act via extracellular Ca2+, tyrosine kinases and/or PKA-
dependent opening of vascular smooth muscle K+ channels124. While an adipocyte-
derived relaxing factor would be potentially beneficial to vascular function, some 
investigators hypothesize that the vasodilatory capacity of perivascular adipose tissue is 
decreased in the setting of obesity131. While adiponectin was initially proposed to be the 
mediating agent of this effect, a recent study demonstrated that perivascular adipose 
tissue from adiponectin gene-deficient mice maintained anti-contractile activity130. 
Hence, no study to date has successfully identified or characterized an adipocyte-
derived relaxing factor(s).     
In contrast to adipocyte-derived relaxing factors, there are several clinical and 
correlative observations that suggest perivascular adipose tissue directly contributes to 
coronary artery disease. In general, perivascular adipose tissue normally surrounds 
large conduit vessels of the heart. Importantly, coronary atherosclerotic disease primarily 
occurs in these larger arteries that are encased by adipose tissue. Perivascular adipose 
volume is also increased in obese patients and animals 116, 132-134. Interestingly, patients 
with a myocardial bridge interrupting perivascular adipose tissue have been documented 
to have limited atherosclerosis within the portion of the vessel underneath the muscle135. 
Together, these observations prompted many to speculate that local epicardial adipose 
tissue directly contributes to vascular dysfunction and disease.    
Clinical findings further support a causative role for perivascular adipose tissue. 
Results from Baker et al.49 and Cheng et al.47 documented pathogenic adipokine profiles 
from human perivascular and epicardial adipose tissue. Specifically, Baker et al. 
reported increased macrophage infiltration (and potentially increased inflammation) 
within epicardial adipose compared to abdominal adipose tissue49. Coronary 
perivascular adipose tissue, therefore, appears to provide a local source of harmful 
factors and adipokines that may directly influence cardiovascular disease. This 
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observation is critical as plasma inflammatory biomarkers may not adequately reflect 
local tissue inflammation, and traditional cardiovascular therapies do not directly target 
local inflammatory signals from perivascular adipose tissue117, 118.  
With the previous findings in mind, many investigators have suggested that 
epicardial adipose tissue should be considered a risk factor for coronary atherosclerosis. 
Notably, recent clinical findings documented that patients with atherosclerotic lesions 
had significantly larger epicardial adipose tissue volumes than patients without 
atherosclerosis116. In comparison to the Framingham risk score (which accounts for age, 
systolic blood pressure, total cholesterol, and smoking status) epicardial adipose tissue 
volume was by far the strongest predictor of coronary atherosclerosis (odds ratios of 2.8 
vs. 4.1). Importantly, no association was found between BMI and coronary 
atherosclerosis.   
Together, the current research on perivascular adipose tissue is indeed 
promising. Both experimental and clinical findings have already increased our 
recognition of the paracrine activity of visceral adipose tissue, and its potential link to 
coronary artery disease (Figure 1-11). However, it is important to recognize that prior 
investigations are largely correlative in nature. Above all, no investigation has 
established a direct, causal link between perivascular adipose tissue and coronary artery 
disease.       
Summary and Proposed Experimental Aims 
The epidemic of obesity is an urgent health crisis. If unabated, the diseases and 
complications associated with obesity will undoubtedly stress healthcare systems, and 
ultimately result in decreased quality of living for millions of people worldwide. 
Particularly alarming is the increased incidence of the multifaceted MetS and associated 
risk for cardiovascular disease. While many studies have sought to identify indicators of 
cardiometabolic risk (i.e. BMI and/or waist-to-hip ratio), our ability to predict the 
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occurrence and severity of such complications remains limited. Hence, much work is still 
needed before we fully understand the link between obesity and cardiovascular disease.    
 To this end, many investigations have repeatedly demonstrated that adipose 
tissue is an active endocrine and paracrine signaling organ. Adipokines have been 
shown to influence metabolism, coagulation, inflammation, and vascular reactivity. 
These findings, in conjunction with altered adipokine production in the setting of obesity, 
have led to the proposed ―Adipokine Hypothesis‖ linking obesity and vascular 
dysfunction. Importantly, visceral adiposity appears to confer unique risks towards the 
development of chronic inflammation and cardiovascular disease. In the end, adipokines 
are thought to contribute to vascular dysfunction within both the coronary micro- and 
macrovascular circulation.  
Lastly, recent evidence strongly suggests that local perivascular adipose tissue 
directly contributes to coronary vascular disease. In particular, perivascular adipose 
tissue is increased with obesity, and has proven to be an abundant source of harmful 
adipokines (Figure 1-12). Notably, recent clinical findings demonstrate that pericardial 
adipose volume is by far the strongest independent predictor of coronary 
atherosclerosis116. While these observations are promising, no investigation has to date 
elucidated a direct, causative mechanism linking perivascular adipose tissue and 
coronary artery disease.       
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Figure 1-12 Perivascular adipose tissue and coronary atherosclerosis. Schematic 
representation of the proposed contribution of perivascular adipose tissue to coronary 
artery dysfunction and disease. Perivascular adipose-derived factors may influence a 
number of stages involved in the development of atherosclerotic lesions. However, to 
date no investigation has successfully elucidated a specific mechanism linking 
perivascular adipose with coronary artery disease. Modified from Lau et al., AJP, 
2005107.  
 With these theories in mind, the central focus of this work is to investigate the 
potential role of coronary perivascular adipose tissue in the development of coronary 
endothelial dysfunction and atherosclerosis. Specifically, the goal of the following studies 
is to determine the cellular/molecular mechanisms by which local perivascular adipose 
tissue regulates vascular reactivity in health, and in the setting of the MetS. These 
objectives will be addressed in studies designed to examine the following Specific Aims 
(Figure 1-13): 
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1. Test the hypothesis that perivascular adipose tissue significantly impairs 
normal coronary vascular reactivity. Rationale for Aim 1 is based primarily on the 
previously mentioned studies suggesting that perivascular adipose tissue has an 
anti-contractile effect on vascular reactivity. We aim to specifically test the effect of 
perivascular adipose tissue from normal canines in the coronary circulation.  
2. Delineate the mechanisms by which perivascular adipose tissue impairs 
coronary endothelial-dependent vasodilation. We hypothesize that perivascular 
adipose tissue impairs coronary endothelial function via a protein kinase C (PKC)-β 
dependent, site-specific phosphorylation of nitric oxide synthase at the amino acid 
residue Thr495. Rationale for our hypothesis is based on the well documented role of 
PKC-β as a mediator of endothelial dysfunction136-139.  
3. Identify the specific perivascular adipose-derived factor(s) that contribute to 
coronary vascular dysfunction in the MetS. We hypothesize that the adipokine 
leptin significantly contributes to the coronary endothelial effects of perivascular 
adipose tissue via PKC-β. Rationale for this hypothesis is based in our laboratory’s 
previous observation of acute leptin-induced coronary endothelial dysfunction36.  
 In the end, findings from these proposed investigations will be among the first to 
provide a specific mechanism by which perivascular adipose tissue affects coronary 
endothelial function, and potentially contributes to vascular disease. Additionally, the 
proposed investigations would suggest that the adipokine leptin is critical in the initiation 
of obesity-associated atherosclerotic disease.   
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Figure 1-13 Proposed mechanism of how perivascular adipose contributes to 
coronary vascular disease. We propose that inflammatory mediators and adipokines 
from perivascular adipose tissue directly impair coronary endothelial function through a 
PKC-β dependent mechanism.  
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Abstract 
Adipocytokines may be the molecular link between obesity and vascular disease. 
However, the effects of these factors on coronary vascular function have not been 
discerned. Accordingly, the goal of this investigation was to delineate the mechanisms 
by which endogenous adipose-derived factors affect coronary vascular endothelial 
function. Both isolated canine coronary arteries and coronary blood flow in anesthetized 
dogs were studied with and without exposure to adipose tissue. Infusion of adipose-
conditioned buffer directly into the coronary circulation did not change baseline 
hemodynamics; however, endothelial-dependent vasodilation to bradykinin was impaired 
both in vitro and in vivo. Coronary vasodilation to sodium nitroprusside was unaltered by 
adipose tissue. Oxygen radical formation did not cause the impairment because 
quantified dihydroethidium staining was decreased by adipose tissue and neither a 
superoxide dismutase mimetic nor catalase improved endothelial function. Inhibition of 
nitric oxide (NO) synthase with L-NAME diminished bradykinin-mediated relaxations and 
eliminated the subsequent vascular effects of adipose tissue. In vitro measurement of 
NO demonstrated that adipose tissue exposure quickly lowered baseline NO and 
abolished bradykinin-induced NO production. The results indicate that adipose tissue 
releases factor(s) that selectively impair endothelial-dependent dilation via inhibition of 
NO synthase-mediated NO production.  
 
Keywords: coronary circulation, perivascular adipose tissue, vascular endothelium, 
adipocytokine; nitric oxide 
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Introduction 
Adipose tissue is an active endocrine and paracrine organ that releases a variety 
of cytokines that influence many physiologic and pathophysiologic conditions 107. Recent 
studies have implicated perivascular adipose tissue in the pathogenesis of vascular 
dysfunction and disease140-143. Adipocyte production of pathogenic adipocytokines and/or 
chemokines have been shown to stimulate chemotaxis 141, inflammation 44, smooth 
muscle proliferation 144 and activate key mediators of atherogenesis 107. These 
potentially harmful adipocytokines have been speculated to promote coronary 
atherogenesis via local paracrine and vasocrine pathways 133. In addition, perivascular 
adipose tissue has also been shown to significantly attenuate contractile responses of 
rat aorta 124-126, 145, rat mesenteric 127, 128 and human internal thoracic arteries 129 to a 
variety of vasoconstrictor compounds. However, there are also abnormalities of 
vasodilation associated with adipocytokines. Our laboratory recently demonstrated that 
the adipocytokines leptin and resistin significantly impair canine coronary endothelial-
dependent vasodilation both in vivo and in vitro 36, 43 in normal animals. As might be 
expected, we have also demonstrated that obesity and insulin resistance alter the 
control of coronary blood flow and significantly impair the balance between oxygen 
delivery and myocardial metabolism 79. This vascular dysfunction is related to 
sensitization of key coronary vasoconstrictor pathways 89, 143, 146, some of which could be 
influenced by factors released from adipose tissue.  
The goal of the present investigation was to delineate the mechanisms by which 
endogenous adipose-derived factors affect coronary vascular endothelial production of 
nitric oxide (NO) at the level of both microvessels and conduit arteries. Potential 
mechanisms were examined by in vitro studies in isolated canine coronary arteries with 
or without perivascular adipose tissue as well as in vivo experiments in open-chest 
anesthetized dogs to evaluate microvascular resistance regulation by endothelial 
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vasodilators before and during treatment with adipose-conditioned buffer. This approach 
was used to document the effects of adipose tissue on coronary vascular reactivity in 
large arteries in vitro where coronary disease predominantly occurs as well as coronary 
flow responses in vivo which reflect alterations in function of microvascular resistance 
vessels.   
Methods 
This investigation was approved by the Institutional Animal Care and Use 
Committee in accordance with the Guide for the Care and Use of Laboratory Animals 
(NIH Pub. No. 85-23, Revised 1996). All dogs studied were lean mongrel dogs weighing 
between 20 and 30 kg.   
Functional assessment of isolated epicardial coronary rings. Isolated coronary 
artery studies were performed as previously described 36, 43. Briefly, left circumflex 
coronary arteries from lean dogs were dissected from the heart with or without the 
naturally occurring perivascular adipose tissue surrounding the conduit artery. 
Representative coronary arteries with or without perivascular adipose tissue were 
stained with Sudan IV and are shown in Figure 2-1.  The arteries were cut into 3 mm 
rings and mounted in organ baths for isometric tension studies. Perivascular adipose 
tissue was either rigorously removed from the arterial rings or allowed to remain intact 
(approximately 0.25 g adipose per ring). Optimal length was found by assessing 
contraction to 60 mM KCl. Passive tension was increased in gram increments until there 
was < 10% change in active KCl contractions.  
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Figure 2-1 Representative isolated left circumflex coronary arteries with or without 
perivascular adipose tissue stained with Sudan IV (adipose tissue staining red). 
 
Endothelial function was assessed by the addition of graded concentrations of 
bradykinin (0.1 nM/L - 10 µM/L, n = 5) or sodium nitroprusside (1.0 nM/L - 0.1mM/L, n = 
3) to the tissue bath. In additional studies, bradykinin concentration responses were 
conducted in the presence of the NO synthase inhibitor N-nitro-L-arginine methyl ester 
(L-NAME, 300 µM/L, n = 7), the superoxide dismutase mimetic tempol (10 µM/L, n = 3), 
and the H2O2 degrading enzyme catalase (1000 U/ml, n = 4). All results obtained during 
bradykinin and sodium nitroprusside dose response experiments are reported as the 
percent relaxation for each animal (Figures 2-3, 2-4, 2-5 and 2-6). 100 percent relaxation 
is defined as a return to the level of tension prior to U46619 contraction.      
Coronary blood flow evaluation of microvascular performance. Dogs were initially 
sedated with morphine (3 mg/kg, sc) and anesthetized with α-chloralose (100 mg/kg, iv). 
The animals were then intubated and mechanically ventilated (Harvard respirator) with 
room air supplemented with oxygen. A catheter was placed in the right femoral vein for 
intravenous administration of supplemental anesthetic and sodium bicarbonate. The 
femoral artery was then cannulated to supply blood to an extracorporeal perfusion 
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system which subsequently perfused the left anterior descending coronary artery (LAD) 
at a controlled pressure. A left lateral thoractomy was performed to expose the heart, 
and the LAD was isolated distal to its first major diagonal branch. After the administration 
of heparin (500 U/kg, iv) the LAD was cannulated with a stainless steel cannula (3 mm 
external diameter, 2.2 mm internal diameter). Coronary perfusion pressure was 
measured through a saline filled catheter advanced to the orifice of the LAD cannula. 
The pressure of the perfusion system was held constant at 100 mmHg by a servo-
controlled roller pump. Similarly, an in line Transonic Systems flow transducer (Ithaca, 
NY) was used in the perfusion system to measure coronary blood flow. Data were 
continuously recorded on IOX data acquisition software from Emka Technologies (Falls 
Church, VA). The preparation was allowed a ~30 minute recovery time before data were 
recorded for analysis.  
In order to test the effects of endogenous adipose-derived factors on coronary 
microvascular endothelial function in vivo, bradykinin was infused (0.3 – 3.0 µg/min) in 
the absence and presence of adipose conditioned buffer (n = 6). The adipose-
conditioned buffer was prepared in phosphate buffered saline that was allowed to shake 
and mix with parietal pericardial adipose tissue (3 g/ml) for 30 min at 37°C in a shaking 
water bath. The conditioned buffer was then filtered (0.2 µm) and infused directly into the 
coronary circulation via the perfusion system (0.3 ml/min). In additional studies, 
bradykinin was simultaneously infused with either L-NAME (150 µg/min, n = 5) or tempol 
(10 mg/min, n = 5). Lastly, studies were also conducted to determine if adipose-
conditioned buffer had any direct effect on coronary hemodynamics. During these 
studies, adipose-conditioned buffer was infused at various rates (0.3 – 3.0 ml/min, n = 3) 
without the administration of bradykinin.   
Nitric oxide measurements. NO concentration was measured in isolated coronary 
arteries (n = 3) before and during exposure to 400 nM bradykinin with or without the 
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addition of perivascular adipose tissue. This concentration of bradykinin was a 
supramaximal concentration for NO production by isolated arterial segments. NO was 
evaluated by a polarographic technique, using a carbon fiber, recessed-tip glass 
microelectrodes as previously described 147. The microelectrodes had a sharpened outer 
tip diameter of 7 – 10 µm and were polarized at +0.7 or +0.9 V relative to either a World 
Precision Instruments carbon fiber reference electrode (Sarasota, FL) or a simple silver-
silver chloride electrode. The currents generated ranged from 0 – 20 pA. A calibration 
curve was established by measurement of the microelectrode current at NO 
concentrations of 0, 600, and 1,200 nM. These concentrations were based on the 
composition of the NO-N2 precision
 calibration gases in saline at 37.5°C. The working 
resolution of the microelectrodes is typically <10 nM, allowing for random noise and 
current drift. The microelectrodes are completely insensitive to oxygen when positively 
polarized. 
Rings of vessel were placed in a perfused bath (5 ml/min, 5 ml bath volume) of 
media similar to that used for tension studies and equilibrated with 95% oxygen and 5% 
carbon dioxide.  The tip of the NO microelectrode was placed in the lumen of the vessel 
and touched an endothelial surface.  The baseline concentration of NO was measured 
followed by the response to bradykinin (400 nM).  Thereafter, the adipose tissue 
removed from the arterial ring was placed upstream of the ring in the flowing media for 
30 minutes before repeating the NO measurements at rest and during bradykinin 
exposure. 
Dihydroethidium staining. Dihydroethidium (DHE) staining for superoxide (O2
-) 
was carried out as described previously 43. Left circumflex coronary arteries with (n = 5) 
and without (n = 5) perivascular adipose tissue were incubated with 10 µM DHE at 37°C 
for 30 min with or without tempol (10 µM/L) administration. The arteries were embedded 
in OCT and flash frozen in liquid nitrogen. Tissue sections (10 µm) were then prepared 
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using a cryostat on thaw-mounted slides. Ethidium fluorescence was assessed with 508 
nm excitation and 615 nm emissions. Scion Image for Windows was used to perform 
histogram analysis of brightness in images of DHE-stained arteries. 
Adipokine content in adipose tissue extract. A multiplexed biomarker 
immunoassay from Linco Laboratories was used to measure the concentration of key 
adipokines in the adipose-conditioned buffer (Table 2-2). The assay was conducted 
according to the manufacturer’s specifications. Briefly, the assay functions by using 
antibody coated beads, which are selective for specific human adipokines. Adipose-
conditioned buffer samples used during the in vivo studies were collected, filtered (0.2 
µm) and individually measured in triplicate on a 96 well plate.  The antibody coated 
beads were incubated with each individual sample and allowed to bind overnight. 
Biotinylated detection antibodies were added to each well, and streptavidin-
phycoerythrin was subsequently added in order to detect the fluorescence on each 
bead. A Luminex Instrument was used to both identify which adipokines were expressed 
and to quantify their relative concentrations.               
 Statistical analyses. Data are presented as mean ± standard error. For both in 
vitro and in vivo studies, a two-way repeated measures ANOVA was used to test the 
effects of the presence or absence of adipose tissue or conditioned buffer (Factor A) and 
various doses of sodium nitroprusside or bradykinin (Factor B) on coronary physical or 
chemical responses (Sigma Stat 3.0 Software). Identical statistics were performed for 
studies conducted in the presence of L-NAME, tempol and catalase. For the in vitro 
experiments, data were analyzed per animal. When statistical differences were found by 
ANOVA, a Student-Newman-Keuls multiple comparison test was performed. The 
criterion for statistical significance was P < 0.05 in all tests. 
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Results 
 Adipose tissue and baseline hemodynamics. Data shown in Figure 2-2 
demonstrate that increases in the intracoronary infusion rate of the adipose-conditioned 
buffer (0.3 – 3.0 ml/min) did not significantly affect baseline coronary blood flow (P = 
0.68). Effects of adipose-conditioned buffer, L-NAME and tempol on baseline coronary 
blood flow, mean aortic pressure and heart rate are given in Table 2-1. Intracoronary 
infusion of adipose-conditioned buffer (0.3 mL/min) did not significantly affect coronary 
blood flow (P = 0.58), mean aortic pressure (P = 0.96) or heart rate (P = 0.89).  Baseline 
coronary hemodynamics were also unaffected by adipose-conditioned buffer in the 
presence of L-NAME (P = 0.58) or the superoxide dismutase mimetic tempol (P = 0.19).  
The average concentrations of adipokines in adipose-conditioned buffer are presented in 
Table 2-2. Notably, the concentration of resistin was substantially greater than the other 
adipokines. 
 
Figure 2-2 Direct infusion of endogenous adipose-derived factors from adipose-
conditioned buffer into canine coronary circulation has no effect on baseline coronary 
blood flow (n = 3). 
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Table 2-1  Effects of adipose-conditioned buffer, L-NAME and tempol on 
baseline hemodynamic data in anesthetized, open-chest dogs. 
        
  
Coronary Blood Flow 
(ml/min/g) 
Aortic Pressure 
(mmHg) 
Heart Rate 
(beats/min) 
Untreated    
    Control (n=6) 0.50 ± 0.01  103 ± 6 87 ± 13 
    Buffer   (n=6) 0.61 ± 0.05 96 ± 9 110 ± 24 
    
L-NAME    
    Control (n=5) 0.45 ± 0.05 105 ± 8 72 ± 9 
    Buffer   (n=5) 0.50 ± 0.08 103 ± 9 90 ± 11 
    
Tempol    
    Control (n=5) 0.69 ± 0.03 102 ± 9 77 ± 10 
    Buffer   (n=5) 0.94 ± 0.15 98 ± 12 94 ± 8 
        
Values are mean ± SE. n = number of dogs.    
 
 Adipose tissue and coronary endothelial function. Adipose-conditioned buffer 
exposure significantly attenuated coronary endothelial-dependent vasodilation, as 
judged by blood flow responses, to the higher doses of bradykinin (1-3 µg/min; ~10 nM 
bradykinin) in open-chest anesthetized dogs (Figure 2-3A; P < 0.01). In isolated 
coronary arteries, arterial relaxation to bradykinin was also decreased by perivascular 
adipose tissue (Figure 2-3B; 1-100 nM; P < 0.01). In contrast, adipose tissue did not 
significantly affect endothelial-independent relaxation to sodium nitroprusside in isolated 
arteries (Figure 2-4). 
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Figure 2-3 Adipose tissue significantly attenuates coronary endothelial-dependent 
vasodilation to bradykinin in vivo (3A, n = 6) and in isolated coronary arteries (3B, n = 5). 
* = P < 0.01. 
 
 
Figure 2-4 Adipose tissue has no significant effect on coronary endothelial-
independent vasodilation to sodium nitroprusside (SNP) n = 3. 
 
 Adipose tissue and coronary reactive oxygen species. DHE staining for 
coronary O2
- showed a significant decrease (67 ± 7% of control) in tempol-sensitive 
fluorescence between arteries with perivascular adipose tissue relative to arteries fully 
cleaned of adipose tissue (Figures 2-5A and 2-5B). Therefore, vessel exposure to 
adipose tissue did not increase O2
- formation. Additional studies demonstrated that the 
administration of tempol (10 µM) to scavenge oxygen radicals did not improve reactivity 
of arteries with perivascular adipose tissue to bradykinin (Figure 2-5D). Instead, tempol 
significantly impaired relaxation of arteries, with or without adipose tissue, to bradykinin 
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(Figure 2-5C and 2-5D, P < 0.001). These findings were confirmed by additional in vivo 
studies in Figure 2-5E which found that tempol failed to reverse the adipose tissue-
induced impairment of bradykinin-mediated coronary vasodilation in open-chest dogs 
(Figure 2-5E, P < 0.001). To test for H2O2 effects, catalase was applied prior to in vitro 
relaxation studies. Enzymatic degradation of H2O2 with catalase diminished the 
relaxation to bradykinin at 1 nM to 30 nM (Figure 2-5F) in comparison to the control 
relaxation shown in Figure 2-5C.  However, arteries with perivascular adipose tissue 
continued to display further impairment (P < 0.01) to bradykinin. 
 Adipose tissue and nitric oxide production. Inhibition of NO synthase with L-
NAME eliminated the relaxation differences between coronary artery rings with or 
without perivascular adipose tissue (Figure 2-6A, P = 0.32). Also note that compared to 
responses of untreated vessels in Figure 2-3B, L-NAME caused a right shift of the dose-
relaxation curve indicating major suppression of endothelial dependent relaxation. These 
initial observations were further supported by in vivo studies demonstrating that 
pretreatment with L-NAME abolished the effect of adipose-conditioned buffer on 
bradykinin-mediated coronary vasodilation (Figure 2-6B; P = 0.24). Again, L-NAME 
caused a significant attenuation of the dose-blood flow response curve indicating major 
suppression of endothelial dependent relaxation in the in vivo coronary microvasculature 
(Figure 2-3A vs. Figure 2-6B). Importantly, measures of coronary NO concentration with 
an NO sensitive microelectrode showed that adipose tissue both markedly lowered basal 
NO production by 60% and eliminated coronary endothelial NO production in response 
to bradykinin (Figue 2-6C, P < 0.05).   
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Figure 2-5 DHE staining showed a significant decrease in fluorescence in coronary 
arteries with perivascular adipose tissue (Representative pictures A and B; inset shows 
average DHE fluorescence). The superoxide dismutase mimetic tempol did not improve 
reactivity of coronary arteries with perivascular adipose tissue (D); rather it significantly 
impaired reactivity of arteries without (C) and with (D) adipose tissue (n = 3). In addition, 
tempol also failed to improve reactivity in vivo (E, n = 5). * P < 0.001. Enzymatic 
degradation of peroxide (H2O2) with catalase also did not reverse the endothelial 
impairment *P < 0.01 (F, n = 4). 
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Figure 2-6 Inhibition of nitric oxide synthase with L-NAME reversed the effect of 
adipose tissue on bradykinin-mediated vasodilation in isolated coronary arteries (A, n = 
7) and in open-chest anesthetized dogs (B, n = 5). Perivascular adipose tissue markedly 
impaired bradykinin (400 nM)-mediated increases in NO production (C, n = 3). 
Table 2-2  Adipokine expression in adipose-conditioned buffer. A multiplexed biomarker 
immunoassay was conducted in order to measure adipokine concentrations present 
within the adipose-conditioned buffer 
  
Adipokines Concentration in adipose-conditioned 
buffer (pg/ml) 
TNF-α  0.04 ± 0.01  
IL-1β  0.24 ± 0.02  
PAI-1(active)  0.42 ± 0.08  
MCP-1  0.45 ± 0.01  
HGF  1.64 ± 0.20  
Leptin  2.40 ± 0.20  
Resistin  5338.00 ± 1032.00  
Values are mean ± SE for all measured samples (n = 10). IL-1 β – interleukin 1β, PAI-1 - 
plasminogen activator inhibitor 1, MCP-1 - monocyte chemoattractant protein-1, HGF - 
hepatocyte growth factor. 
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Discussion 
 The present investigation was designed to examine the mechanisms by which 
endogenous adipose-derived factors might impair coronary endothelial function within 
both the coronary microcirculation and conduit arteries.  The major new findings from 
this study are that factor(s) released from adipose tissue: 1) do not affect baseline 
coronary blood flow or systemic hemodynamics; 2) significantly impair endothelial-
dependent vasodilation to bradykinin in both in vivo preparations and isolated coronary 
arteries; 3) do not alter coronary endothelial-independent vasodilation to sodium 
nitroprusside, i.e. vascular smooth muscle response to NO; 4) do not significantly 
increase coronary O2
- production or H2O2-mediated vasodilation; and 5) markedly 
attenuate coronary artery endothelial production of NO in isolated vessels. Taken 
together, these data indicate that adipose tissue releases factor(s) that selectively impair 
endothelial-dependent dilation via inhibition of NO synthase-mediated NO production. 
This impairment is independent of alterations in coronary vascular smooth muscle 
response to NO, O2
- mediated decreases in NO-bioavailability or H2O2-mediated 
coronary vasodilation. 
     Adipose tissue and baseline coronary hemodynamics. Before trying to interpret 
any effect of adipose tissue, it was necessary to test the direct effect of adipose-derived 
factors on baseline coronary blood flow, arterial pressure and heart rate (Figure 2-2 and 
Table 2-1). Our results indicate that factors released by adipose tissue do not directly 
affect overall coronary microvascular resistance under normal resting conditions. 
Importantly, the present findings are consistent with earlier studies and the current L-
NAME studies (Table 2-1) which demonstrated that blockade of NO synthase-mediated 
NO production has little effect on baseline coronary blood flow 72, 74.   
 Effects of adipose tissue on coronary endothelial function. Data from this study 
are the first to document that endogenous factors released from adipose tissue 
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selectively inhibit coronary endothelial-dependent dilation to bradykinin judged both by in 
vivo measures of coronary blood flow (regulated predominantly by microvessels; Figures 
2-3, 2-5, and 2-6), by relaxation of isolated coronary arteries (where atherosclerotic 
disease predominantly occurs; Figure 2-3) and by in vitro measurement of NO (Figure 2-
6C). Our findings indicate that the adipose-induced impairment of coronary endothelial 
function is mediated by a selective impairment of NO synthase mediated NO production 
because the effect of adipose tissue on bradykinin-mediated dilation was reversed by L-
NAME (Figure 2-6A-B) and direct measures of NO demonstrated a decline in both basal 
NO and bradykinin stimulated NO production (Figure 2-6C). We propose that the 
impaired relaxation is specific to NO generation as we did not detect any effect of 
adipose tissue on relaxations to sodium nitroprusside (Figure 2-4) or to bradykinin in the 
presence of L-NAME (Figure 2-6), suggesting that adipose tissue does not affect dilation 
to prostacyclin or endothelial-derived hyperpolarizing factors. 
 The findings documented in this investigation are potentially marred by a few 
concerns. First, there was a potential that the measured endothelial impairment was 
simply an artifact of decreasing responses to bradykinin after repeated doses (i.e. 
tachyphylaxis). However, a recent study from our laboratory demonstrated no 
tachyphylaxis to repeated treatments of bradykinin both in vivo in open-chest 
anesthetized dogs and in vitro in isolated coronary arteries (4). Hence any measured 
experimental differences in bradykinin-mediated dilation are not an artifact of repeated 
bradykinin dose-response curves.  Second, the isometric tension and NO production 
measurements were done under circumstances where there was at most a trivial 
amount of hemoglobin, oxyhemoglobin or myoglobin. Therefore, these iron containing 
organ compounds were highly unlikely to suppress NO bioavailability 142, 148, 149. This 
conclusion is further supported by our in vivo coronary flow data.   
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 Adipose tissue and coronary reactive oxygen species. Recently, many 
investigations have focused on the role of reactive oxygen species in regulating 
endothelial function 150, 151. Specifically, O2
- has been shown to decrease NO 
bioavailability by reacting to produce peroxynitrite 152. Additional studies have also 
shown that H2O2 acts as an endothelium-derived hyperpolarizing factor and metabolic 
vasodilator of the coronary circulation 151, 153-155. Together, both O2
- and H2O2 are 
potential direct and/or indirect mediators of the observed endothelial dysfunction caused 
by adipose tissue. The fact that DHE staining of arteries with perivascular adipose tissue 
showed a significant decrease in fluorescence (Figure 2-5A and B) argues that adipose 
tissue does not impair coronary endothelial-dependent vasodilation via increases in O2
- 
production. This is supported by additional in vitro and in vivo studies with tempol that 
showed this O2
- dismutase mimetic did not significantly improve the adipose tissue 
induced impairment of bradykinin-mediated coronary vasodilation (Figure 2-5C, D, and 
E). In fact, administration of tempol significantly decreased bradykinin-mediated 
relaxation suggesting that O2
- may function as a vasodilator, a hypothesis supported by 
other recent investigations 156-159. Enzymatic degradation of H2O2 with catalase also 
failed to reverse adipose-induced endothelial impairment (Figure 2-5F). Taken together 
these important data argue against O2
- or H2O2 as a mechanism of adipose-induced 
coronary endothelial dysfunction.  
Identity of adipose tissue derived vasoactive factor(s). We performed a ―targeted‖ 
immunoassay to measure the expression of key adipocytokines in adipose-conditioned 
buffer (Table 2-2). This assay was in no way exhaustive of all potential adipose-derived 
mediators; however this approach allowed us to identify candidate adipokines that could 
contribute to the adipose-induced endothelial impairment. It is important to point out that 
the use of anti-human antibodies for this canine adipose tissue assay was an 
unavoidable limitation of this assay. However, it should be pointed out that there was no 
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clear correlation between the % homology of human vs. canine adipokine protein 
sequences (ranged from 63 – 92%) and the measured adipokine concentrations (Table 
2-2) which suggests that antibody specificity alone was not the reason for the low 
concentrations measured.  
Using this targeted immunoassay we found that resistin levels were markedly 
high relative to the other measured adipokines (5.9 ± 1.4 ng/ml, Table 2-2). This resistin 
concentration results in an estimated average plasma concentration of 0.19 ± 0.09 
ng/ml, which is significantly lower than concentrations reported in human plasma 160, 161 
and the 10 ng/ml that our laboratory (4) as well as others (17; 33) previously 
demonstrated to impair coronary endothelial-dependent vasodilation. Additionally, the 
present study found that L-NAME reversed the effect of adipose tissue on bradykinin-
mediated dilation (Figure 2-6A and B) but an early study from our laboratory showed that 
L-NAME failed to inhibit resistin-induced suppression of bradykinin dilation (4). These 
findings do not support resistin as the primary mechanism of adipose-induced coronary 
endothelial dysfunction.  
Other adipokines could potentially contribute the observed coronary effects of 
adipose tissue. Recently, our laboratory found that leptin induces significant impairment 
of coronary endothelial-dependent vasodilation 36. However, the measured concentration 
of leptin in the adipose-conditioned buffer (2.40 ± 0.20 pg/ml) is substantially lower than 
the ~10 ng/ml previously found to be necessary for leptin-induced coronary endothelial 
dysfunction 36. Therefore, as was the case for resistin, the functional concentration for 
leptin was below the pathologic concentration that negatively influenced endothelial-
dependent dilation. Alternatively, TNF-α and long chain fatty acids have both been 
shown to attenuate endothelial-dependent vasodilation, albeit via mechanisms that 
elevate oxidative stress/O2
- production 57, 140, 162 which is inconsistent with our findings 
with adipose tissue (Figure 2-5). Therefore, at present it is difficult to attribute the 
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adipose-induced impairment to any known adipocytokine. However, it is plausible that 
several different adipose-derived factors could act in an additive and/or synergistic 
manner to diminish coronary NO production. Clearly future studies are needed to identify 
the exact adipose-derived factor(s) and cellular/molecular mechanisms involved. 
In conclusion, results from this study are the first to demonstrate that 
endogenous adipose-derived factors diminish production of coronary endothelial NO as 
judged by pharmacological challenges and direct measurements of endothelial NO. The 
overall findings implicate that adipocytokines have the ability to rapidly depress coronary 
microvascular and arterial NO generation. It is important to note that during in vivo 
circumstances, perivascular adipose tissue has little or no access to the endothelial cells 
of either arteries or arterioles. We are only demonstrating that adipose tissue contains 
factors that when released and circulated throughout the heart cause potentially dire 
consequences for endothelial mediated dilation. These results provide us with a new 
potential explanation of how alterations in adipokine expression in obesity may 
contribute to the development of vascular dysfunction and coronary atherosclerosis. 
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Chapter 3  
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Abstract  
Endogenous perivascular adipose-derived factors have been shown to contribute 
to coronary vascular regulation by impairing endothelial function through direct inhibition 
of endothelial nitric oxide synthase (eNOS). However, our understanding of the 
underlying mechanisms remains uncertain. Accordingly, this study was designed to test 
the hypothesis that perivascular adipose tissue releases agents that attenuate coronary 
endothelial nitric oxide production via a protein kinase C (PKC)-β dependent 
mechanism. Isometric tension studies were conducted on isolated canine circumflex 
coronary arteries with and without natural amounts of perivascular adipose tissue. 
Adipose tissue significantly diminished coronary endothelial-dependent vasodilation and 
nitric oxide production in response to bradykinin and acetylcholine. Selective inhibition of 
endothelial PKC-β with ruboxistaurin (1 µM) abolished adipose-induced impairment of 
bradykinin-mediated coronary vasodilation and endothelial production of nitric oxide. 
Western blot analysis revealed a significant increase in eNOS phosphorylation at the 
inhibitory residue Thr495 in arteries exposed to perivascular adipose tissue. This site-
specific phosphorylation of eNOS was prevented by inhibition of PKC-β. These data 
demonstrate that perivascular adipose-derived factors impair coronary endothelial nitric 
oxide production via a PKC-β dependent, site-specific phosphorylation of eNOS at 
Thr495.  
 
KEYWORDS: coronary circulation, perivascular adipose tissue, adipokine, endothelial 
nitric oxide synthase, protein kinase C-β 
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Introduction  
In recent years, investigators have increasingly recognized adipose tissue as 
both an active endocrine and paracrine organ.  As a signaling organ, the production of 
adipose-derived cytokines (adipokines) has been well documented to influence many 
physiologic and pathophysiologic conditions107. Specifically, adipokine production has 
been shown to influence a number of pathogenic pathways, including chemotaxis141, 
inflammation44, smooth muscle proliferation144 and other key mediators of 
atherogenesis107. Although adipokines have been proposed to be the molecular link 
between obesity and cardiovascular disease107, the exact relationship between adipose 
tissue and vascular function remains uncertain. Studies have implicated the surrounding 
perivascular adipose tissue as a local source of adipokines that contribute to both 
vascular function and disease47, 118, 163, 164. Coronary atherosclerotic disease frequently 
occurs in large arteries encased by adipose tissue164, while the opposite is true of arterial 
segments located underneath myocardial bridges lacking perivascular adipose tissue135. 
Together, these observations suggest that vascular function and disease is partly 
dependent on the presence of perivascular adipose tissue.   
Recent work from our laboratory documented that perivascular adipose tissue 
significantly impaired coronary endothelial function in response to bradykinin both in vitro 
and in vivo, further implicating local adipose tissue in the initiation and pathogenesis of 
coronary vascular disease165.  In particular, we documented that adipose-derived factors 
diminished endothelial nitric oxide (NO) production through direct inhibition of NO 
synthase (NOS). This effect was independent of changes in oxidative stress, peroxide-
mediated vasodilation and was not related to alterations in smooth muscle 
responsiveness to NO. These findings are important because dysfunction and injury of 
the vascular endothelium is widely accepted to be a critical precursor to the development 
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of atherosclerosis101. However, no investigation has successfully identified the 
mechanisms by which perivascular adipose-derived factor(s) impair coronary endothelial 
function. 
Our current understanding of vascular disease would suggest that perivascular 
adipose tissue may serve as a paracrine source of harmful inflammatory adipokines. 
However, few studies have characterized how perivascular adipose tissue contributes to 
normal, healthy coronary endothelial function. Recent findings call attention to specific 
adipokines such as interleukins, TNF-α and leptin as potential perivascular adipose-
derived factors altering endothelial function47, 136, 165. Although promising, these 
investigations have yet to clearly identify the exact paracrine mediators of coronary 
endothelial impairment. Furthermore, the task of identifying key mediators from 
perivascular adipose tissue without additional experimental evidence may prove to be 
arduous. Accordingly, the purpose of the present study was to delineate a common 
signaling pathway for perivascular adipose tissue-induced endothelial dysfunction. 
We propose that perivascular adipose tissue attenuates coronary endothelial NO 
production via a protein kinase C (PKC)-β dependent, site-specific phosphorylation of 
endothelial NO synthase (eNOS) at Thr495.  PKC is a known negative regulator of eNOS 
activity and NO production166. Specifically, phosphorylation of eNOS at the inhibitory 
Thr495 site significantly diminishes enzymatic activity by disrupting the binding of 
Ca2+/Calmodulin to eNOS167, 168. Further justification for our hypothesis is based on the 
well documented role of PKC-β as a mediator of endothelial dysfunction136-139. Two 
recent clinical trials observed that inhibition of this specific, predominately endothelial 
isoform of PKC markedly improved both macrovascular139 and microvascular138 
endothelial function in type II diabetic patients. Similarly, additional investigations 
suggest that endothelial impairment as a result of increased adiposity and/or adipokine 
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release is potentially linked with PKC activity136, 137. However, to date no investigation 
has directly examined if PKC activity contributes to perivascular adipose-induced 
endothelial dysfunction.  
Methods  
This investigation was approved by the Institutional Animal Care and Use 
Committee in accordance with the Guide for the Care and Use of Laboratory Animals 
(NIH Pub. No. 85-23, Revised 1996). Seven lean, mongrel dogs weighing between 20 
and 30 kg were used for all experiments. Dogs were euthanized with a lethal intravenous 
dose of pentobarbital (86 mg / Kg dog weight). After confirming cardiac arrest, a left 
lateral thoracotomy was performed to collect the heart.    
Functional assessment of isolated epicardial coronary rings. Isolated coronary 
artery studies were performed as previously described36, 43. Briefly, left circumflex 
coronary arteries from lean dogs were dissected with or without the naturally 
surrounding perivascular adipose tissue (approximately 0.25 g adipose per ring). 
Arteries and perivascular adipose tissue were always taken from the same animal and 
collected at the same time. Care was taken to isolate the same 2-3 cm proximal portion 
of the circumflex artery that is naturally surrounded by perivascular adipose tissue. 
Arteries were cut into 3 mm rings and mounted in organ baths for isometric tension 
studies. To avoid any confounding differences between proximal and distal portions of 
the artery, the surrounding adipose was dissected off of every other arterial ring. Optimal 
length was found by assessing contraction to 60 mM KCl. Arteries were pre-contracted 
with the thromboxane A2 mimetic U46619 (1 µM) in order to functionally assess 
endothelial function. Specifically, endothelial function was assessed by the addition of 
graded concentrations of bradykinin (0.1 nM/L-10 µM/L, n = 5) or acetylcholine (1 nM/L – 
10 µM, n = 4) to the tissue bath. Some arteries without adipose tissue were also 
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incubated with the NO synthase inhibitor L-NAME (300 µM) prior to the dose response 
experiments. In additional studies, bradykinin concentration responses were conducted 
in the presence of the general PKC inhibitor Ro 31-8220 (1 µM, n = 7) or the PKC-β 
specific inhibitor ruboxistaurin (1 µM, n = 6). All results obtained during bradykinin dose 
response experiments are reported as the percent relaxation for arterial rings from 
individual animals (Figures 3-1 and 3-2). 100 percent relaxation was defined as a return 
to the level of tension prior to thromboxane A2 mimetic (U46619) contraction.  
Tissue collection and western blot analysis. Coronary arteries from lean dogs (n 
= 3 dogs) were isolated and incubated in 5 mL organ baths for approximately one hour 
at 4°C in Krebs buffered solution. All arteries used for protein analysis were cleaned of 
perivascular adipose tissue. Control arteries were allowed to incubate alone, while other 
arteries were incubated with either 3 g of perivascular adipose (floating in the bath) or 
both adipose and ruboxistaurin. Following incubation, arteries were immediately placed 
in liquid N2 and stored at -80C for western blot analysis as previously described
169-171. 
Following protein isolation, equivalent amounts of protein were loaded onto 10% 
acrylamide gels for electrophoresis and blotting. After blocking for 1 h at ambient 
temperature, membranes were incubated overnight at 4C with primary antibodies 
directed against eNOS and phosphorylated eNOS Thr495 (both 1:1000; Affinity 
BioReagents and BD Transduction Laboratories). Blots were washed and incubated with 
goat anti-rabbit or anti-mouse IgG-HRP secondary antibodies (1:5000; Santa Cruz 
Biotechnology) for 1.5 h at ambient temperature. Blots were then stripped and reprobed 
with β-actin antiserum (1:5000; Santa Cruz Biotechnology) as the internal control. 
Immunoreactivity was visualized using an ECL western blotting detection kit (GE 
Healthcare) and quantified by scanning densitometry (Bio-Rad Quantity One 1-D 
Analysis Software).  
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Nitric oxide measurements. NO concentration was measured in isolated coronary 
arteries (n = 3) before and during exposure to 400 nM bradykinin with or without the 
addition of perivascular adipose tissue as previously described165. NO was evaluated by 
a polarographic technique, using a carbon fiber, recessed-tip glass microelectrode147. 
This microelectrode has previously been demonstrated to not be sensitive to NO 
synthase inhibitors, including L-NAME and nitroarginine formed by L-NAME when 
properly constructed with a Nafion barrier. eNOS blockade dramatically reduces the NO 
signal, indicating measurement of endothelium derived NO172, 173.  After placing arterial 
rings into a media perfused organ bath, the tip of the NO microelectrode was positioned 
within the vessel lumen and pushed against the endothelial surface to insure a stable, 
close contact.  Baseline concentrations of NO were measured followed by the response 
to bradykinin and a washout.  Arterial rings were then treated with ruboxistaurin (1 µM) 
for approximately 30 min before repeating NO measurements. Finally, perivascular 
adipose tissue was added to the flowing media upstream of the artery for an additional 
30 minutes, and a similar experimental protocol was conducted.  
Statistical analyses. Data are presented as mean ± standard error. For isometric 
tension studies, two-way ANOVA was used to test the effects of the perivascular 
adipose and various doses of bradykinin, while t-test analysis was used to compare half 
maximal effective concentration (EC50) values (Sigma Stat 3.0 Software). A two-way 
repeated measures ANOVA was used to analyze western blot densities and NO 
measurements. All experiments were analyzed per animal. When statistical differences 
were found a Student-Newman-Keuls multiple comparison test was performed. The 
criterion for statistical significance was P < 0.05 in all tests. 
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Results 
 Perivascular adipose tissue and coronary endothelial function. To examine 
the effects of endogenous perivascular adipose-derived factors on coronary endothelial 
function, isometric tension studies were conducted in isolated coronary arteries with and 
without perivascular adipose tissue. Consistent with our recent data165, we found that the 
presence of perivascular adipose tissue significantly decreased coronary endothelial-
dependent vasodilation (Figure 3-1). Specifically, perivascular adipose attenuated 
arterial relaxation to both bradykinin in the concentration range from 1 nM to 320 nM (P 
< 0.001, Figure 3-1B), and acetylcholine in the concentration range from 32 nM to 
100nM (P < 0.001, Figure 3-1A). Adipose tissue also increased the EC50 of bradykinin 
from 4.0 ± 1.2 nM to 14.7 ± 2.4 nM (P < 0.01), and of acetylcholine from 35.4 ± 10.5 nM 
to 89.7 ± 9.3 nM (P < 0.05). Perivascular adipose tissue had no effect on the maximal 
vasodilatory response to bradykinin (98 ± 2%) or acetylcholine (88.9 ± 3%). Additional 
experiments with clean arterial rings in the presence of the NO synthase inhibitor L-
NAME (300 µM) demonstrated that pharmacologic inhibition of NO production was 
similar to the effect of perivascular adipose tissue alone. In particular, there was a 
modest difference between control arteries treated with L-NAME and arteries with 
perivascular adipose tissue in response to acetylcholine (P < 0.05, Figure 3-1A), while 
no difference was observed in response to bradykinin (P = 0.81, Figure 3-1B).    
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Figure 3-1 A. Perivascular adipose tissue caused significant impairment of 
acetylcholine-mediated vasodilation in isolated coronary arteries (32 – 100 nM 
acetylcholine, n = 4). B. Likewise, perivascular adipose tissue also significantly impaired 
endothelial response to bradykinin (1 – 320 nM bradykinin, n = 5). Importantly, arteries 
with perivascular adipose tissue responded similarly to control arteries treated with the 
NO synthase inhibitor L-NAME (A and B). * P < 0.01 for adipose tissue vs. control. 
+
 P < 
0.05 for adipose tissue vs. control +L-NAME. 
 Protein Kinase C and adipose-induced impairment of coronary endothelial 
function. To test the hypothesis that PKC-β mediates perivascular adipose-induced 
endothelial impairment, we conducted additional isometric tension studies with different 
inhibitors of PKC. Administration of the general PKC inhibitor Ro-31-8220 (1 µM) or the 
PKC-β specific inhibitor ruboxistaurin (1 µM) eliminated the effect of perivascular 
adipose on bradykinin-induced coronary vasodilation (Figure 3-2; P = 0.49 vs. P = 0.86, 
respectively). Both Ro-31-8220 and ruboxistaurin had no effect on the vasodilation of 
control arteries without adipose tissue as the EC50 values were not statistically different 
(Ro-31-8220 EC50 = 2.5 ± 1.3 nM; ruboxistaurin EC50 = 2.7 ± 1.0 nM).  Pretreatment with 
Ro-31-8220 and ruboxistaurin significantly enhanced endothelial-dependent vasodilation 
in arteries with perivascular adipose tissue, and maintained EC50 values at control levels 
(Ro-31-8220 EC50 = 2.4 ± 1.0 nM; ruboxistaurin EC50 = 2.2 ± 0.5 nM; P < 0.001 vs. 
untreated).  
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Figure 3-2 A. Administration of the general PKC inhibitor Ro 31-8220 eliminated the 
difference between arteries with and without perivascular adipose (P = 0.49; n = 7). B. 
Similarly, the PKC-β specific inhibitor ruboxistaurin eliminated differences between both 
groups (P = 0.86; n = 6). 
Perivascular adipose and phosphorylation of eNOS. Compared to untreated-
control arterial segments, incubation of coronary arteries with perivascular adipose 
tissue significantly increased the degree of site-specific eNOS phosphorylation at the 
inhibitory Thr495 residue (~140 kDal; Figure 3-3; P < 0.01). This increase in eNOS 
phosphorylation was prevented by pretreatment of arteries with ruboxistaurin (P = 0.23). 
No differences in expression of total eNOS or β–actin were noted between treatments 
(Figure 3-3; P = 0.30 and P = 0.41 respectively). In order to assess relative changes in 
the phosphorylation state of eNOS the ratio of phosphorylated eNOS-Thr495 to total 
eNOS (P-eNOS/eNOS) was calculated. We found that the P-eNOS/eNOS ratio was 
significantly elevated for arteries treated with perivascular adipose tissue (Figure 3-3; P 
< 0.01). This specific increase in the phosphorylation state of eNOS was prevented by 
pretreatment of arteries with ruboxistaurin. 
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Figure 3-3 Representative western blot staining for phosphorylated eNOSThr495 (P-
eNOSThr495 and total eNOS ~140 kD) in coronary arteries. Arteries were either untreated 
(Control), treated with perivascular adipose (PVAT) or treated with both ruboxistaurin 
and perivascular adipose tissue (PVAT +Ruboxistaurin). Arteries treated with only 
perivascular adipose displayed increased fluorescence for P-eNOSThr495 and had a 
significantly greater ratio of P-eNOSThr495 to total eNOS (n=3). * P < 0.01. 
 
 Protein kinase C, perivascular adipose and NO production. Additional 
experiments were also conducted to determine if inhibition of PKC-β improves coronary 
endothelial NO production in response to bradykinin in the presence of perivascular 
adipose tissue. Previously, we documented that perivascular adipose-derived factors 
significantly diminish both baseline and bradykinin-stimulated increases in coronary 
endothelial NO production (P < 0.05)165. In the present study, we found that baseline NO 
concentration averaged 292 ± 65 nM in untreated control arteries. Under control 
conditions, administration of bradykinin increased NO production by 193.3 ± 38 nM 
(Figure 3-4). Pretreatment of arteries with ruboxistaurin did not significantly affect either 
baseline or bradykinin-stimulated NO production. In contrast, the addition of perivascular 
adipose tissue dramatically decreased NO production, and bradykinin failed to 
significantly increase coronary NO production. Finally, pretreatment of arteries with 
ruboxistaurin prevented this effect of perivascular adipose tissue, as the increase in 
coronary NO production was similar to control conditions.    
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Figure 3-4 Endothelial-derived NO was measured with a NO-sensitive microelectrode. 
The change in NO production (delta NO) in response to bradykinin (400 nM) is illustrated 
for each experimental condition. Pretreatment with ruboxistaurin protected endothelial 
function and maintained bradykinin-stimulated NO production in the presence of 
perivascular adipose tissue (n = 3). * P < 0.01 compared to all other conditions. 
Discussion 
 The present investigation was designed to elucidate the specific 
cellular/molecular mechanism by which perivascular adipose tissue impairs coronary 
endothelial function. We hypothesized that PKC, a known negative regulator of eNOS, 
was a key mediator of adipose-induced endothelial dysfunction. The major new findings 
of this study include: 1) Perivascular adipose-derived factors impair both bradykinin and 
acetylcholine-mediated vasodilation and NO production through direct inhibition of eNOS 
activity (Figure 3-1); 2) perivascular-adipose induced impairment of endothelium-
dependent vasodilation is similar to pharmacologic inhibition of NO synthase (Figure 3-
1); 3) selective inhibition of PKC-β prevents perivascular-adipose induced endothelial 
dysfunction in isolated coronary arteries (Figures 3-2 and 3-4); 4) factors released from 
perivascular adipose tissue increase site-specific phosphorylation of eNOS at the 
inhibitory Thr495 residue (Figure 3-3); 5) PKC-β inhibition significantly decreases the level 
of eNOS phosphorylation at Thr495 and 6) blockade of PKC-β prevents decreases in 
coronary endothelial NO production induced by perivascular adipose tissue (Figure 3-3). 
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Taken together, these results indicate that perivascular adipose tissue releases factor(s) 
that selectively impair endothelial-dependent dilation via a PKC-β dependent 
phosphorylation of eNOS at Thr495.    
 In order to address the growing prevalence of cardiovascular disease, recent 
investigations have attempted to better understand both the natural and 
pathophysiologic relationship between perivascular adipose tissue and vascular function. 
Initial investigations suggested that perivascular adipose significantly attenuated the 
contractile responses of rat aorta124-126, 145, rat mesenteric127, 128, and human internal 
thoracic arteries129 through the release of an adipose-derived relaxing factor (ADRF). 
While these initial findings suggest a role for local adipose in regulating arterial tone, it is 
hard to ignore the mounting evidence that perivascular adipose disrupts normal 
endothelial function and potentially contributes to atherogenesis47, 118, 163, 164. Previous 
studies have documented that coronary perivascular adipose tissue increases with 
obesity 132-134, and could serve as a visceral link between inflammatory adipokines 
released during obesity and cardiovascular disease44, 49, 174. In particular, recent work 
from our laboratory was the first to document that factor(s) released by coronary 
perivascular adipose tissue rapidly inhibit NO production and concurrently attenuate 
coronary endothelial-dependent vasodilation165. Importantly, we found that perivascular 
adipose tissue had no effect on coronary smooth muscle response to NO, superoxide 
(O2
-) production or hydrogen peroxide (H2O2) mediated vasodilation.  
 The current findings confirm these previous observations (Figures 3-1 and 3-4), 
and demonstrate that perivascular adipose tissue has a generalized impairment of 
eNOS activity that is not limited to specific endothelium-dependent vasodilators (i.e. 
impairment of both bradykinin of acetylcholine).  These observations implicate 
perivascular adipose-derived factors as a local regulator of endothelial function. More 
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specifically, local adipose-derived factors appear to ―restrain‖ the normal endothelium 
derived NO produced by the underlying coronary vessels of lean animals (Figures 3-1 
and 3-4). While our observation that naturally occurring adipose tissue impairs coronary 
endothelial function may seem troublesome, several key points must be considered. 
First, the effect of perivascular adipose tissue is unlikely to be systemic throughout the 
coronary circulation as only the conduit, non-resistance vessels have significant 
perivascular adipose. Second, the present findings demonstrate that impaired NO 
production is the primary cause of attenuated endothelial response (Figure 3-1A and B). 
Decreased NO production from these conduit, non-resistance arteries would minimally 
impair vascular regulation as blockade of NO synthesis alone produces little change in 
coronary blood flow175-177. Therefore, the present findings represent only a modest 
change in reactivity of the coronary vascular bed. However, these findings importantly 
suggest that perivascular adipose tissue could be a potential contributor to endothelial 
dysfunction and atherogenesis. However, future investigations are needed to more 
thoroughly examine this hypothesis in the setting of obesity. 
 Results from the present investigation indicate that perivascular adipose-induced 
impairment of coronary endothelial NO production is mediated via a PKC-β dependent 
pathway (Figures 3-2 through 3-4). Earlier studies have documented a potential 
relationship among obesity, PKC-β and endothelial dysfunction136-139. In particular, 
Tinsley et. al. found that interleukin-1beta (IL-1β), IL-6, and tumor necrosis factor-alpha 
(TNF-α) can independently increase PKC activation, gap formation, and 
hyperpermeability across an endothelial monolayer136. Likewise, results from the Bohlen 
laboratory demonstrated that inhibition of PKC-β substantially reversed endothelial 
dysfunction in Zucker obese rats137, while recent clinical trials have documented 
improved peripheral macrovascular endothelial function in type-II diabetic patients 
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treated with ruboxistaurin139. The present investigation extends these previous findings 
by implicating visceral coronary perivascular adipose tissue as an anatomic link between 
increased PKC activity and endothelial impairment. Present findings therefore connect a 
proposed mediator of cardiovascular disease with a local adipose depot, further 
suggesting that perivascular adipose-derived factors may contribute to the development 
of vascular dysfunction and disease.  
 Our data also indicate that perivascular adipose tissue impairs coronary 
endothelial NO production via site specific phosphorylation of eNOS by PKC-β at the key 
inhibitory residue Thr495. This finding agrees with previous investigations documenting 
that phosphorylation of eNOS at Thr495 by PKC decreases NO production and disrupts 
protein-protein interaction between eNOS and calmodulin168, 178, 179. Hence, perivascular 
adipose-derived factors increase the basal phosphorylation state of eNOS-Thr495, 
thereby impairing coronary endothelial increases in NO production. However, the current 
findings extend these previous studies by implicating a direct role for the β isoform of 
PKC in eNOS phosphorylation. It is important to note that eNOS is regulated by a very 
complex network of kinases (protein kinase A, B and C), phosphatases (Protein 
phosphatases 1 and 2), co-factors (i.e. tetrahydrobiopterin, flavin mononucleotide and 
nicotinamide adenine dinucleotide phosphate), protein-protein interactions and sub-
cellular localization166. In general, many of these eNOS regulators have been shown to 
influence eNOS activity during disease states. In particular, phosphorylation of the 
Serine 1177 (Ser1177) residue is thought to be among the most critical regulatory sites for 
eNOS activation166. Furthermore, disruption of Ser1177 residue180 and altered availability 
of tetrahydrobiopterin181-183 have both been shown to increase eNOS production of O2
-. 
These observations are in direct contrast to our recent data which found no involvement 
of O2
- in perivascular adipose-induced endothelial dysfunction165. Although still uncertain, 
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recent data also supports a role for Ser116 as an inhibitory site of eNOS (when 
phosphorylated)184. Hence, alternative mechanisms for perivascular adipose-induced 
endothelial dysfunction exist. However, it is important to recognize that the PKC-β 
inhibitor ruboxistaurin prevented adipose-induced decreases in endothelial-dependent 
dilation and NO production (Figures 3-2 and 3-4), as well as increases in eNOS-Thr495 
phosphorylation (Figure 3-3). Therefore, our present findings argue against a significant 
role for these alternative pathways. 
 To date, no investigation has successfully identified the perivascular adipose-
derived factor(s) that impair coronary endothelial function. However, the known 
association between PKC-β and endothelial dysfunction suggests that the active 
agent(s) released from perivascular adipose tissue are likely harmful inflammatory 
adipokines that are known to be elevated during obesity. Importantly, results from 
Tinsley et al. suggest a potential role for interleukins and TNF-α as perivascular adipose-
derived factors mediating endothelial dysfunction136. These data are consistent with our 
recent findings which documented that perivascular adipose tissue expresses 
appreciable concentrations of resistin, leptin, IL-1β and TNF-α165. Importantly, each of 
these factors has been shown to independently produce endothelial dysfunction36, 43, 57, 
136. In addition, other investigations have detected the presence of leptin, TNF-α and 
other adipokines in coronary perivascular adipose tissue47, 165. The present results 
importantly implicate a common PKC-β dependent pathway by which perivascular 
adipose-derived mediators induce coronary endothelial dysfunction. In addition, our 
findings support the ―outside to inside‖ 40, 185, 186 signaling paradigm for perivascular 
adipose-derived factors in the pathogenesis of coronary vascular disease as well as 
PKC-β as a therapeutic target to improve endothelial function. Although our data 
establish a mechanistic link between perivascular adipose tissue and diminished 
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coronary endothelial NO production, additional studies are needed to examine the 
effects of perivascular adipose-derived adipokines in the setting of obesity and the MetS.   
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Abstract 
Factors released by perivascular adipose tissue (PVAT) have been documented 
to disrupt coronary endothelial function via phosphorylation of eNOS by PKC-β. 
However, our understanding of how PVAT contributes to coronary vascular disease as a 
complication of obesity/metabolic syndrome (MetS) remains limited. The current study 
investigated the mechanism by which adipose-derived factors impair coronary vascular 
function in MetS. Coronary arteries with and without PVAT were collected from lean or 
MetS Ossabaw miniature swine for isometric tension studies. Endothelial-dependent 
vasodilation to bradykinin was significantly reduced in MetS. PVAT did not affect 
bradykinin-mediated dilation in arteries from lean swine, but significantly exacerbated 
endothelial dysfunction in arteries from MetS swine. This PVAT-induced impairment was 
reversed by inhibition of either PKC-β with ruboxistaurin or leptin receptor signaling with 
a recombinant, pegylated leptin antagonist. Immunohistochemistry and western 
analyses revealed a marked increase in PVAT leptin expression in MetS swine. 
Additional studies found that coronary endothelial dysfunction induced by leptin alone 
was reversed by ruboxistaurin. Together, these findings indicate that increases in PVAT 
leptin expression exacerbate coronary endothelial dysfunction in MetS via a PKC-β 
dependent pathway. Our findings importantly implicate perivascular adipose-derived 
leptin as a pro-atherogenic mediator of coronary disease in MetS. 
 
KEYWORDS: endothelial dysfunction, epicardial adipose tissue, perivascular adipose 
tissue, leptin, PKC-β, obesity 
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Introduction  
The epidemic of obesity remains a daunting challenge for healthcare in the 
United States. Increased adiposity is associated with the metabolic syndrome (MetS); a 
known constellation of cardiovascular risk factors including insulin resistance, impaired 
glucose tolerance, hypertension, and dyslipidemia4, 8. Furthermore, as each component 
of the MetS is an independent risk factor for cardiovascular disease, it is not surprising 
that MetS exacerbates many cardiovascular diseases including stroke, coronary artery 
disease, and myocardial infarction5, 6, 8. Importantly, adipose tissue is now widely 
accepted as an active endocrine and paracrine organ. As a signaling organ, the 
production of adipose-derived cytokines (adipokines) has been well documented to 
influence many physiologic and pathophysiologic conditions107. Specifically, adipokine 
production has been shown to influence key pathogenic mediators of atherogenesis107 
including chemotaxis141, inflammation44, endothelial function48 and smooth muscle 
proliferation144. Although adipokines have been proposed to be the molecular link 
between obesity and cardiovascular disease107, the exact relationship between adipose 
tissue and vascular disease remains uncertain.  
Recent studies have implicated adipose tissue that normally surrounds large 
coronary arteries, i.e. perivascular adipose tissue (PVAT), as a local source of 
adipokines that contribute to both vascular dysfunction and atherosclerotic disease47, 116, 
118, 163, 164. This contention is supported by data indicating that coronary atherosclerotic 
plaques primarily occur in the larger epicardial arteries encased by PVAT164 as well as 
other findings illustrating a positive association between epicardial PVAT volume and the 
severity of coronary artery disease116, 187. In particular, a recent investigation from Greif 
et al. documented that PVAT volume, hypoadiponectinemia, and inflammation represent 
the strongest risk factors for the presence of coronary atherosclerosis116. While 
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intriguing, evidence thus far is largely correlative, and no investigation has established a 
direct, causal link between PVAT and coronary artery disease.         
Other investigations have recently documented that epicardial PVAT from 
patients with the MetS express significantly higher levels of harmful adipokines such as 
tumor necrosis factor (TNF)-α, interleukin (IL)-6, and leptin47. This increase in PVAT 
adipokine expression is consistent with the marked degree of endothelial dysfunction71, 79 
and atherosclerotic disease188, 189 typically observed in the setting of the MetS. In 
particular, hyperleptinemia initiates several deleterious vascular events including 
proinflammatory cytokine production190-192 and neointimal growth193. In particular, our 
laboratory has previously demonstrated that hyperleptinemia significantly impairs 
endothelial-dependent relaxation both in vivo and in vitro36.  In spite of this, 
hyperleptinemia in the setting of obesity displays only a modest association with 
coronary heart disease114. These findings suggest that our understanding of MetS and 
adipokine pathology remains limited, and that additional mechanisms are likely 
responsible. 
Our laboratory has demonstrated that factors released by PVAT in normal lean 
animals significantly impair coronary endothelial-dependent vasodilation and nitric oxide 
(NO) production via direct inhibition of NO synthase, both in vitro and in vivo165. 
Additional studies have shown that PVAT-induced endothelial impairment occurs via 
protein kinase C (PKC)-β dependent phosphorylation of endothelial NO synthase 
(eNOS) at the inhibitory amino acid residue Thr495 194.  These findings are important 
because they establish a mechanistic link between local cardiac PVAT and coronary 
vascular function. However, the degree to which alterations in PVAT adipokine 
expression in MetS affects coronary vascular dysfunction/disease (i.e. endothelial 
dysfunction101) has yet to be examined.  
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 The purpose of the present investigation was to test the hypothesis that 
augmented PVAT-derived leptin exacerbates underlying coronary endothelial 
dysfunction in the MetS through a PKC-β dependent pathway. This hypothesis was 
tested in Ossabaw miniature swine fed either a normal maintenance diet (11% kcal from 
fat) or an excess calorie atherogenic diet (45% kcal from fat, 2% cholesterol, 20% kcal 
from fructose) that induces classic clinical features of the MetS171, 195, 196. Finally, 
vascular reactivity was assessed in isolated coronary arteries with or without the 
normally surrounding PVAT. 
Methods 
Swine model of metabolic syndrome. This investigation was approved by the 
Institutional Animal Care and Use Committee in accordance with the Guide for the Care 
and Use of Laboratory Animals (NIH Pub. No. 85-23, Revised 1996). Lean swine were 
fed ~2200 kcal/day of standard chow (5L80, Purina TestDiet, Richmond, IN) containing 
18% kcal from protein, 71% kcal from complex carbohydrates, and 11% kcal from fat. 
MetS swine were fed an excess ~8000 kcal/day high fat/fructose, atherogenic diet 
containing 17% kcal from protein, 20% kcal from complex carbohydrates, 20% kcal from 
fructose, and 43% kcal from fat (lard and hydrogenated soybean and coconut oils), and 
supplemented with 2.0% cholesterol and 0.7% sodium cholate by weight (5B4L, Purina 
TestDiet, Richmond, IN).  Prior to sacrifice, blood was drawn for glucose, insulin, and 
lipid assays 171, 195, 196.  
Functional assessment of isolated epicardial coronary rings. Isolated coronary 
artery studies were performed for both experimental groups as previously described43, 
146, 165, 194. Briefly, left anterior descending (LAD) coronary arteries were dissected with or 
without the naturally surrounding perivascular adipose tissue (approximately 0.25 - 0.50g 
adipose per ring). Arteries and perivascular adipose tissue were always taken from the 
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same animal and collected at the same time. Care was taken to isolate the same 2 - 3 
cm proximal portion of the circumflex artery that is naturally surrounded by perivascular 
adipose tissue. Arteries were cut into 3 mm rings and mounted in organ baths for 
isometric tension studies (Figure 4-1). Optimal length was found by assessing 
contraction to 60 mM KCl, and the arteries were pre-contracted with the thromboxane A2 
mimetic U46619 (1µM).  Vascular function was assessed by the addition of graded 
concentrations of the bradykinin (0.1 nM/L - 10 µM/L, n = 7 lean; n = 9 MetS) or sodium 
nitroprusside (1.0 nM – 0.1 mM, n = 4 lean; n = 6 MetS) to the tissue bath. In additional 
studies with arteries from MetS swine, bradykinin concentration responses were 
conducted in the presence of the PKC-β specific inhibitor ruboxistaurin (1 µM, n = 6) or a 
recombinant, pegylated leptin receptor antagonist (1 µM, n = 4, Protein Laboratories 
Rehovot)  All results obtained during dose response experiments are reported as the 
percent relaxation for arterial rings from individual animals (Figures 4-2, 4-3 and 4-5). 
100 percent relaxation was defined as the resulting tension following the administration 
of nitroglycerin (20 µM). 
Immunohistochemical analysis. Segments of isolated coronary arteries with the 
surrounding PVAT were collected, immediately fixed by immersion in 10% formalin, and 
processed in paraffin for histological analysis according to manufacturer’s specifications 
(Zymed Laboratories, Inc.). Briefly, paraffin-embedded tissue sections were initially 
rehydrated. Prior to blocking, antigen retrieval was performed in a citrate buffer (0.1 M). 
Tissue sections were then incubated overnight at 4°C with polyclonal antibodies directed 
against leptin (1:100; Abcam).  Sections were then rinsed and incubated with an anti-
rabbit biotinylated antibody followed by a tertiary streptavidin peroxidase conjugate 
(Zymed Laboratories, Inc.). Tissue sections were developed with a five minute exposure 
to 3-amino-9-ethyl-carbazole (AEC) and counter stained with hemotoxylin. 
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Representative photomicrographs were obtained using standard light microscopy (Nikon 
Spot camera system).       
Western blot analysis. Western blotting was performed as previously described 
(n = 4)146, 171, 194. Tissues were isolated and immediately placed in liquid N2 and stored at 
-80C. PVAT was homogenized, centrifuged, and the resulting supernatants were 
collected for analysis. Equivalent amounts of protein were loaded onto 15% acrylamide 
gels for electrophoresis and blotting. After blocking for 1 h at ambient temperature with 
5% nonfat milk, membranes were incubated overnight at 4C with the same leptin 
polyclonal antibody that was used for immunohistochemical analysis (1:1000; Abcam). 
Blots were washed and incubated with donkey anti-rabbit IgG-HRP secondary antibody 
(1:4000; Santa Cruz Biotechnology) for 1 h at ambient temperature. The same blots 
were stripped and reblotted with β-actin antiserum (1:3000; Santa Cruz Biotechnology) 
as the internal control to confirm equal protein loading. Immunoreactivity was visualized 
using an ECL western blotting detection kit (GE Healthcare) and quantified by scanning 
densitometry (Bio-Rad Quantity One 1-D Analysis Software).  
Statistical analyses. Data are presented as mean ± standard error. For isometric 
tension studies, a two-way ANOVA was used to test the effects of the perivascular 
adipose (Factor A) and various drugs (Factor B) on coronary dilator responsiveness. A t-
test was used to compare half maximal effective concentration (EC50) values (Sigma 
Stat 3.0 Software). All experiments were analyzed per animal. When statistical 
differences were found with ANOVA a Student-Newman-Keuls multiple comparison test 
was performed. The criterion for statistical significance was P < 0.05 in all tests. 
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Results 
Representative phenotype of lean and MetS Ossabaw miniature swine. 
Phenotypic characteristics of lean and MetS swine are listed in Table 4-1. Compared to 
their lean counterparts, MetS swine exhibited a 49% increase in body weight (kg), 90% 
increase in fasting glucose, 662% increase in total cholesterol, and 140% increase in 
triglyceride levels. Figure 4-1 illustrates typical isolated arteries collected from lean (A) 
and MetS (B) swine. Note visible coronary atherosclerotic lesions typically observed in 
MetS swine (Figure 4-1B).  
Table 4-1  Phenotypic characteristics of lean and metabolic syndrome Ossabaw swine 
  
Phenotype Lean MetS 
 
Body Weight (kg) 
 
45 ± 4 
 
67 ± 3* 
 
Fasting glucose (mg/dl) 
 
68 ± 4 
 
129 ± 4* 
 
Total cholesterol (mg/dl) 
 
66 ± 4 
 
503 ± 41* 
 
Triglycerides (mg/dl) 
 
 
20 ± 4 
 
48 ± 5* 
Values are mean ± SE for lean (n = 6) and MetS (n = 6) swine. * P < 0.05 vs. Lean. 
 
 
 
 
Figure 4-1 Representative coronary arteries from lean and MetS swine. Arteries 
were cut into 3 mm rings with and without PVAT and mounted in organ baths for in vitro 
isometric tension studies. Arteries were brought to optimal length and pre-contracted 
with the thromboxane A2 mimetic U46619. Note visible neointimal formation in arteries 
from MetS swine (B). 
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Effects of PVAT on coronary vascular function. To examine the effects of 
endogenous perivascular adipose-derived factors on coronary vascular function, 
isometric tension studies were conducted in isolated coronary arteries with and without 
PVAT in lean and MetS swine. In contrast to our previous investigations in canines 165, 
194, lean PVAT had no significant effect on endothelial-dependent vasodilation to 
bradykinin (Figure 4-2A). Furthermore, endothelial-independent vasodilation in response 
to sodium nitroprusside was also unchanged by PVAT (Figure 4-2B).  
On the contrary, the onset of MetS alone caused significant endothelial 
dysfunction that was markedly exacerbated by the presence of PVAT (Figure 4-2A and 
C). Specifically, the EC50 value of bradykinin in MetS coronary arteries without PVAT 
was 9.6 ± 4.3 nM (compared to 1.3 ± 0.5 nM for lean, P < 0.05). Perivascular adipose-
derived factors clearly exacerbated underlying endothelial dysfunction as the EC50 value 
increased ~10-fold from 9.6 ± 4.3 nM to 92.3 ± 32.8 nM (P < 0.05), and bradykinin-
mediated vasodilation was attenuated in the concentration range of 1 nM to 10 μM (P < 
0.001). Importantly, the maximal dilator response to bradykinin (10 μM) was reduced in 
the presence of MetS PVAT from 87 ± 7% to 59± 6% relaxation (P < 0.001). Likewise, 
perivascular adipose-derived factors caused a modest attenuation of endothelial-
independent relaxation to sodium nitroprusside in the concentration range of 100 to 320 
nM (P < 0.01). The maximal response and EC50, however, were not significantly altered 
by MetS PVAT.      
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Figure 4-2 PVAT markedly impairs coronary endothelial-dependent vasodilation in 
MetS swine. PVAT failed to attenuate bradykinin or sodium nitroprusside-induced 
vasodilation in arteries from lean-control animals (A and B). In contrast, arteries from 
MetS swine displayed significant endothelial dysfunction that was markedly exacerbated 
by PVAT (C). PVAT modestly reduced endothelial-independent vasodilation in MetS 
swine (D).   
Protein Kinase C-β and PVAT-induced coronary endothelial dysfunction. To 
test the hypothesis that PKC-β mediates perivascular adipose-induced endothelial 
impairment in MetS swine, we conducted additional isometric tension studies in the 
presence of the PKC-β specific inhibitor ruboxistaurin (1 µM). Consistent with our recent 
data194, administration of ruboxistaurin significantly improved endothelial function in 
MetS swine (Figure 4-3, P < 0.001). Specifically, inhibition of PKC-β improved the EC50 
value in response to bradykinin to 22.1± 11.9 nM (P < 0.05 vs. MetS with PVAT), and 
increased maximal vasodilatory response by ~ 23.5 ± 6.3% (P < 0.05).  
76 
 
 
Figure 4-3 Inhibition of PKC-β improves endothelial function in MetS swine. 
Administration of the PKC-β specific inhibitor ruboxistaurin (1 μM) significantly improved 
endothelial-dependent dilation to bradykinin. This observation supports our previous 
findings, and further suggests that PVAT-derived factors signal through a PKC-β 
dependent pathway.   
Leptin and leptin receptor expression within metabolic syndrome PVAT. To 
begin identifying potential mediating agents of PVAT-induced endothelial impairment, 
immunohistochemical experiments were performed on cross sections of coronary 
arteries with PVAT from both lean and MetS swine. Immunohistochemical analysis of 
lean arteries displayed no evidence of leptin expression in PVAT (data not shown). In 
contrast, positive leptin staining was detected in the surrounding PVAT layer (Figure 4-
4A and B) of coronary arteries from MetS swine. Additional tissue sections were 
prepared to test for the presence endothelial leptin receptors. Importantly, leptin receptor 
staining was strongly detected along the endothelium of coronary vessels from MetS 
swine (Figure 4-4C). This observation is consistent with previous findings from our 
laboratory demonstrating that the long-form leptin receptor is expressed in canine 
coronary arterioles36. Quantitative western blot studies with the same antibody further 
confirmed the expression of leptin within MetS PVAT. In particular, MetS significantly 
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increased leptin protein expression in comparison to lean (Figure 4-5, P < 0.05), while β-
actin expression was unchanged (Data not shown, P = 0.6).  
 
Figure 4-4 Leptin expression in the coronary PVAT of MetS Swine. 
Immunohistochemistry of coronary artery cross sections displayed no evidence of leptin 
staining in lean swine (data not shown). In contrast, leptin staining was evident in PVAT 
from MetS swine (A). Magnified images further display leptin staining within adipocytes 
(B, 100X magnification). Positive leptin receptor staining was also detected along the 
vascular endothelium and neointima (C). Positive staining is denoted by red arrows. 
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Figure 4-5 Leptin expression is significantly increased in the PVAT of MetS Swine. 
Quantitative western blotting analysis was used to validate previous 
immunohistochemistry images. In particular, PVAT-derived leptin was detected in both 
lean and MetS Swine; however, MetS expression was significantly increased.   
78 
 
PVAT-derived leptin and coronary endothelial function. To test the 
hypothesis that local adipose-derived leptin mediates PVAT-induced endothelial 
impairment in MetS swine, we conducted isometric tension studies in the presence of a 
recombinant, pegylated leptin receptor antagonist (200 ng/ml). Administration of this 
leptin signaling antagonist improved endothelial response of MetS swine to bradykinin 
concentrations ranging from 10 nM to 10 μM (Figure 4-6A, P < 0.001). Furthermore, 
inhibition of leptin signaling significantly improved maximal response to bradykinin (P < 
0.001), and tended to improve the EC50 response from 153 ± 60 nM to 29 ± 14 nM (P < 
0.09). 
 Additional ―proof of principle‖ studies were also conducted to determine the 
effects of exogenous leptin alone (30 ng/ml) on coronary arterial rings from lean swine 
without PVAT (Figure 4-6B). Consistent with previous studies36, 93, acute administration 
of leptin attenuated endothelial-dependent dilation to bradykinin (0.32 to 10nM 
bradykinin, P < 0.001), and shifted EC50 response from 1.3 ± .5 to 5.2 ± 1.8 nM (P < 
0.05). Co-administration of leptin and ruboxistaurin (1 M) eliminated the leptin-induced 
endothelial impairment, and restored coronary vascular response to bradykinin.              
 
Figure 4-6 PVAT-derived leptin exacerbates endothelial dysfunction in MetS swine 
through PKC-β. Inhibition of leptin receptor signaling with a recombinant, pegylated 
leptin antagonist (200 ng/ml) fully reversed the effect of PVAT in MetS swine (A). 
Furthermore, acute administration of leptin (30 ng/ml) caused significant endothelial 
impairment in response to bradykinin, which was reversed by the inhibition of PKC-β (B).     
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Discussion 
 Recent investigations have implicated PVAT in the development of coronary 
atherosclerosis47, 116, 118, 163-165, 194. In order to describe a direct link between PVAT and 
coronary artery disease, the present investigation was designed to elucidate the 
mechanism by which perivascular adipose-derived factors diminish coronary endothelial 
function in the setting of MetS. In addition, this investigation sought to identify key 
perivascular adipose-derived agents likely contributing to endothelial impairment. We 
hypothesized that during MetS, perivascular adipose-derived leptin markedly 
exacerbates underlying endothelial dysfunction through a PKC-β dependent 
phosphorylation of eNOS. This purposed mechanism was based on previous findings 
from our laboratory demonstrating that perivascular adipose-derived factors from lean 
canines significantly diminish coronary NO production through PKC-β-dependent 
phosphorylation of NO synthase165, 194.  
 The major new findings of this study include: 1) PVAT-derived factors from lean 
swine have no effect on coronary vascular function; 2) arteries from MetS swine display 
significant endothelial dysfunction that is markedly exacerbated by PVAT; 3) selective 
inhibition of PKC-β improves endothelial response in the presence of PVAT from MetS 
swine; 4) leptin is expressed in the surrounding perivascular adipose layer of MetS 
swine, while leptin receptor is expressed predominantly along the coronary vascular 
endothelium; 5) administration of a recombinant, pegylated leptin antagonist reverses 
the effect of PVAT from MetS swine; 6) acute administration of leptin causes significant 
endothelial impairment through a PKC-β dependent mechanism. Taken together, these 
results indicate that perivascular adipose-derived leptin markedly exacerbates coronary 
endothelial dysfunction in MetS via a PKC-β dependent mechanism.   
80 
 
 Results from the present study are important because they are among the first to 
identify leptin as a causative, perivascular adipose-derived agent that impairs coronary 
endothelial-dependent dilation. Endothelial dysfunction has long been suggested to be 
an initiating event in the development of atherosclerosis101, 104; hence, current results 
provide direct evidence that surrounding PVAT contributes to atherogenesis in MetS. 
Present findings agree with other investigations documenting an attenuating effect of 
PVAT165, 194, and are the first to document that PVAT from MetS swine causes a 
significantly greater impairment of coronary endothelial function. Taken together, these 
initial results underscore the need to consider the local production and paracrine release 
of harmful adipokines from PVAT as a critical link between obesity and coronary 
disease. Hence, the potential diagnostic and therapeutic benefit of monitoring the growth 
and adipokine expression pattern of PVAT should be further investigated for clinical use.  
 Above all, findings from this investigation illustrate the potentially critical 
contribution of leptin to the initiation of coronary atherogenesis. Both 
immunohistochemistry and western blot analysis clearly demonstrate that leptin 
production is elevated in the setting of MetS (Figures 4-4 and 4-5). Numerous 
investigations have documented that hyperleptinemia initiates several deleterious 
vascular events including proinflammatory cytokine production190-192, and neointimal 
growth193. In particular, our laboratory has previously demonstrated that hyperleptinemia 
significantly impairs endothelial-dependent relaxation both in vivo and in vitro36. In 
addition, recent studies have demonstrated that leptin is a potent chemoattractant for 
monocytes and macrophages197. With these previous studies in mind, the current results 
further confirm the deleterious activity of leptin. Furthermore, the observation that a 
leptin antagonist can almost entirely mitigate the effect of PVAT illustrates the 
physiologic importance of perivascular adipose-derived leptin in mediating endothelial 
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dysfunction. These observations highlight the need to consider local anatomy as a 
critical factor in the pathogenesis of coronary artery disease, and suggest that leptin may 
function as a key mediator of ―endothelial injury‖ and initiator of inflammation within the 
surrounding PVAT.  
 Aside from anatomic proximity, results depicted in Figures 4-2 through 4-6 
suggest a potential mechanism of leptin signaling through endothelial receptors to 
ultimately modulate the activity of eNOS via PKC-β. This assertion is based on previous 
results from our laboratory demonstrating that perivascular adipose-derived factors 
significantly diminish endothelial NO production by increasing phosphorylation of eNOS 
by PKC-β at the inhibitory Thr495 residue194. Similarly, the present finding that leptin 
receptors are located along the vascular endothelium agrees with prior investigations 
which demonstrated that the long-form, signaling leptin receptor is expressed by human 
endothelial cells36.  Importantly, the effect of acutely administered leptin on lean coronary 
arteries was completely reversed by inhibition of PKC-β (Figure 4-6B). Hence, this 
investigation is among the first to suggest that leptin receptor signaling is potentially 
coupled with PKC activation activity198, 199. Together, this investigation strongly suggests 
that leptin impairs vascular reactivity through PKC-β in a primarily endothelial-dependent 
(likely eNOS specific) fashion.              
 One concerning observation about the current findings was that perivascular 
adipose tissue from lean swine had no effect on endothelial-dependent relaxation. This 
is in direct contrast to previous investigations from our laboratory demonstrating the 
perivascular adipose tissue from lean, healthy mongrel canines significantly diminished 
endothelial production of NO165, 194. One likely explanation is differences in adipokine 
expression between canines and swine. It is also plausible that leptin is not the 
mediating agent responsible for perivascular adipose-induced endothelial impairment in 
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canines. Specifically, adipokines measured from lean, canine perivascular adipose 
tissue displayed significantly high levels of resistin165. In addition to phenotypic variation 
between species, an additional explanation is that normal (lean) levels of leptin are 
significantly higher in canines than Ossabaw miniature swine. In particular, there is 
approximately a fourfold difference in plasma leptin concentrations for lean canines (~6 
ng/ml)93 in comparison to lean Ossabaw swine (~1.5 ng/ml)195. In the end, the current 
use of a strong model of MetS provides more clinically relevant findings, and further 
promotes the present identification of leptin as a critical perivascular adipose-derived 
agent. 
 Interpretation of the present investigation, however, is limited by our 
understanding of how factors derived from outer adipose tissue effectively communicate 
with endothelial cells within the vascular lumen. Even with growing evidence suggesting 
that mediators originating outside of the coronary vasculature are capable of affecting 
vascular homeostasis, it remains unclear how these factors penetrate into the 
circulation. Importantly, recent investigations have documented that increased coronary 
vasa vasorum neovascularization could provide prompt delivery of perivascular-derived 
factors to the medial and intimal layers of the arterial wall120, 121, 200. Specifically, vasa 
vasorum neovascularization has been demonstrated to occur within the first weeks of 
experimental hypercholesterolemia and precede overt coronary endothelial 
dysfunction120. In context of the current findings, future investigations need to further 
clarify the importance of coronary vasa vasorum for transporting leptin and other 
potential adipokines from perivascular adipose tissue to the arterial wall.    
 The present results implicate leptin as a perivascular adipose-derived factor that 
significantly exacerbates coronary endothelial dysfunction in MetS. This attenuated 
vasodilatory response appears to function via a common PKC-β dependent pathway. 
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Together, this investigation highlights the potential therapeutic benefit of targeting PKC-β 
and epicardial adipose-derived leptin. Above all, this investigation supports the ―outside 
to inside‖ 40, 185, 186 signaling paradigm for perivascular adipose-derived factors, and is the 
first to propose a direct, causative mechanism.  Additional studies are needed to 
examine the physiologic contribution of coronary vasa vasorum to perivascular adipose-
induced endothelial dysfunction and disease.    
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Chapter 5  
 
Discussion 
 The epidemic of obesity continues to intensify in developed nations throughout 
the world. As the prevalence of obesity and MetS increases, healthcare systems will 
undoubtedly be challenged to manage the expected increase of obesity-associated 
cardiovascular disease2. While research throughout the past decades has influenced 
many to acknowledge obesity as an inflammatory and pathologic condition, the exact 
mechanisms linking increased adipose and cardiovascular disease remain poorly 
understood.  
 There is mounting evidence that local visceral epicardial adipose tissue 
contributes to obesity-associated coronary disease. Specifically, perivascular adipose 
tissue surrounding the major conduit coronary arteries has been linked with unfavorable 
cardiometabolic complications115-118. Importantly, recent clinical findings suggest that 
perivascular adipose volume is by far the strongest predictor of coronary 
atherosclerosis116. These findings are novel because they propose an alternative, 
paracrine pathway in the development of vascular disease. However, no investigation 
has established a direct causal link between perivascular adipose tissue and coronary 
artery disease.  
 In an effort to address these developing theories, the central focus of this work 
was to investigate the potential role of coronary perivascular adipose tissue in the 
development of coronary endothelial dysfunction and atherosclerosis. Our goal was to 
determine the cellular/molecular mechanisms by which perivascular adipose tissue 
regulated vascular reactivity in health, and in the setting of the MetS. These objectives 
were addressed by the following Specific Aims: 
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1. Test the hypothesis that perivascular adipose tissue significantly impairs 
normal coronary vascular reactivity. Initial studies in normal, lean canines 
demonstrated that perivascular adipose-derived factors selectively impair coronary 
endothelial-dependent vasodilation via direct inhibition of NO synthase both in vitro 
and in vivo. This effect was independent of alterations in coronary vascular smooth 
muscle responsiveness to NO, O2
- mediated decreases in NO-bioavailability, and/or 
altered H2O2-mediated vasodilation
165.  
2. Delineate the mechanisms by which perivascular adipose tissue impairs 
coronary endothelial-dependent vasodilation. Additional experiments further 
documented that perivascular adipose-derived factors inhibit eNOS-mediated NO 
production in response to both bradykinin and acetylcholine. Importantly, these 
studies discovered that perivascular adipose-derived factors impair coronary 
endothelial NO production via a PKC-β dependent, site-specific phosphorylation of 
eNOS at Thr495. Notably, administration of the PKC-β inhibitor ruboxistaurin 
protected endothelial function and maintained bradykinin-stimulated NO production 
in the presence of perivascular adipose tissue194.  
3. Identify the specific perivascular adipose-derived factor(s) that contribute to 
coronary vascular dysfunction in the metabolic syndrome. Concluding 
experiments established that perivascular adipose tissue in the setting of MetS 
considerably attenuates coronary endothelial function. Above all, these studies 
suggest that perivascular adipose-derived leptin markedly exacerbates underlying 
coronary endothelial dysfunction in MetS via a PKC-β dependent mechanism. Figure 
5-1 summarizes these important findings.      
 
 
86 
 
 
 
 
 
Figure 5-1 Proposed mechanism of how perivascular adipose contributes to 
coronary vascular disease. Results from these investigations suggest that perivascular 
adipose-derived leptin (and potentially other inflammatory mediators and adipokines) 
directly impairs coronary endothelial function through a PKC-β dependent mechanism. 
This perivascular adipose-induced endothelial impairment may be the precipitating event 
in the development of coronary atherosclerosis. 
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Implications 
 Findings from these investigations challenge many currently held theories and 
assumptions regarding coronary circulation and the pathogenesis of vascular disease. In 
particular, results from lean canines and MetS swine suggest that perivascular adipose 
tissue influences both normal and diseased coronary vascular function. These 
observations are compelling, and suggest that several issues central to cardiovascular 
physiology and disease must be reconsidered.   
 
Contribution of Perivascular Adipose Tissue to Normal Coronary Circulation 
Results from this work imply that perivascular adipose tissue is a significant 
regulator of normal, healthy coronary endothelial function. Hence, independent of any 
changes caused by MetS, perivascular adipose tissue appears to naturally restrain 
normal endothelial function of the underlying coronary vessel. While these observations 
may at first glance appear troublesome, several key points must be considered. First, 
the effect of perivascular adipose tissue appears to be limited to the relatively small 
portion of the vascular tree covered in adipose tissue. Any observed endothelial 
impairment is therefore not systemic throughout the entire vascular network.   
Second, the present findings demonstrate that impaired NO production is the 
primary cause of the attenuated endothelial response (Figure 5-2). Results 
demonstrating that the effect of canine perivascular adipose tissue resembles 
pharmacologic inhibition of eNOS with L-NAME strongly suggest that other vasodilator 
pathways (i.e. cyclooxygenase and/or endothelium derived hyperpolarizing factors) are 
minimally altered.  Notably, decreased NO production from these large, conduit arteries 
would modestly impair coronary blood flow regulation, and therefore represents a 
nominal change in the reactivity of the coronary vascular bed. This assertion is based on 
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numerous studies demonstrating the blockade of NO synthesis does not attenuate 
exercise-induced coronary vasodilation175-177, 201. Hence, under normal, lean conditions 
perivascular adipose tissue may minimally impair coronary function and blood supply to 
the heart. 
 
Figure 5-2 Perivascular adipose restrains normal endothelial function. Present 
results suggest that normal, lean perivascular adipose tissue naturally restrains 
endothelial function within the underlying coronary vessel. This impairment appears to 
be predominantly due to attenuated NO production. Importantly, while endothelial 
response is significantly decreased, arteries are still capable of fully relaxing to 
endothelial-dependent vasodilators.     
 With these implications in mind, few investigations have addressed whether 
vascular reactivity changes along the coronary artery with differing amounts of 
perivascular adipose tissue. However, our hypothesis would suggest that increasing the 
amount of perivascular adipose could result in a ―dose-dependent‖ impairment of eNOS 
activity and vasodilation. This implication is important, as clinical studies suggest that 
perivascular adipose tissue is increased with obesity132-134. In addition, both the amount 
of perivascular adipose tissue and the arterial wall thickness decreases as conduit 
coronary arteries travel away from the ostia. As multiple agents potentially diffuse from 
perivascular adipose tissue, the more distal portions of the arteries may be more readily 
affected by surrounding adipose.  
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Together, the present results imply that coronary arteries covered in adipose may 
inadvertently be more susceptible for coronary dysfunction and atherosclerosis. This 
contention is supported by correlative studies reporting that the presence of a 
myocardial bridge suppresses atherosclerotic development within the underlying 
vascular intima135. These observations imply that naturally occurring perivascular 
adipose tissue is a significant regulator vascular reactivity. While the present studies 
focused solely on coronary function, our observations imply that other vascular networks 
commonly surrounded by adipose (i.e. renal or mesenteric arteries) may also be 
significantly affected by local perivascular adipose tissue.    
 
Contribution of Perivascular Adipose Tissue to Coronary Artery Disease 
 In contrast to studies in lean animals, the final experiments directly address the 
issue of perivascular adipose tissue in the setting of MetS. Concluding experiments 
document that obese perivascular adipose tissue markedly exacerbates underlying 
coronary endothelial dysfunction. Given the numerous clinical observations correlating 
perivascular adipose tissue with coronary artery disease, these findings provide direct 
evidence of a paracrine link between epicardial adipose and vascular disease. Above all, 
the current data support our hypothesis that perivascular adipose-derived leptin directly 
mediates endothelial dysfunction through a PKC-β dependent mechanism.  
These studies are the first to demonstrate that perivascular adipose-derived 
factors impair coronary endothelial function through a PKC-β dependent phosphorylation 
of eNOS. Importantly, experimental evidence clearly documents a specific biochemical 
pathway that when preemptively blocked, can effectively protect the endothelium from 
impairment (Figure 5-3A). While these initial experiments did not directly address 
perivascular adipose tissue in the context of obesity, subsequent work demonstrated 
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that PKC-β inhibition markedly improves endothelial response in MetS swine with 
perivascular adipose tissue (Figure 5-3B). Importantly, these observations connect 
epicardial adipose with a known mediator of obesity-associated endothelial 
dysfunction137.  
 
Figure 5-3 Blockade of PKC-β is beneficial to coronary endothelial function in the 
presence of perivascular adipose tissue. In the presence of perivascular adipose 
tissue, the vascular endothelium is unable to produce NO in response to bradykinin. 
Pretreatment with the PKC-β inhibitor ruboxistaurin effectively protects the endothelium, 
and enables endothelial cells to significantly increase NO production in response eNOS 
activation (A)194. In the setting of MetS, administration of ruboxistaurin significantly 
improves endothelial response in the presence of perivascular adipose tissue (B).      
Subsequent experiments further suggest that perivascular adipose-derived leptin 
signals through endothelial leptin receptors to increase PKC-β activity. This assertion is 
consistent with previous investigations from our laboratory illustrating that the long-form 
(OB-Rb) leptin receptor is expressed by human coronary endothelial cells36. More 
importantly, the proposed involvement of PKC in the endothelial leptin signaling cascade 
is an interesting experimental correlation. While no investigation has to date clearly 
illustrated a specific mechanism linking leptin signaling with PKC, several investigations 
have observed similar effects. Specifically, leptin has been observed to regulate human 
platelet aggregation202, insulin receptor signaling199, 203, and colonic mucin production199, 
204 through PKC-dependent pathways. Interestingly, leptin has been shown to alter 
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intracellular calcium mobilization in response to the growth factor lysophosphatidic acid 
(LPA)199, 205. This specific effect was mediated by increased PKC activity coupled to the 
Box 3 motif of the OB-Rb through phosphatidylinositol 3-kinase (PI3K). Taking these 
findings into consideration, the present results imply that endothelial leptin receptors are 
capable of activating PKC at least in part through the PI3K signaling cascade (Figure 5-
4).    
 
Figure 5-4 Potential signaling cascade for leptin-induced endothelial impairment. 
Several investigations document that leptin signals in part through PKC dependent 
pathways. In particular, recent evidence suggests that leptin receptor (OB-Rb) activation 
results in phosphatidylinositol 3-kinase (PI3K) recruitment and PKC activation.   
 Lastly, in light of the metabolic and inflammatory nature of perivascular adipose 
tissue36, 41-45, current findings also underscore the influence adipokines may have on 
systemic cardiovascular function and vascular disease. Interestingly, leptin appears to 
be uniquely positioned as a critical mediator of endothelial dysfunction and arterial 
disease. Previous studies have demonstrated that leptin is a potent chemoattractant for 
circulating monocytes197. Consequently, while present studies clearly demonstrate that 
leptin directly impairs endothelial function, leptin may also promote the initial infiltration 
of inflammatory cells into the surrounding tissue.  
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This ―dual‖ effect of leptin may render the endothelium susceptible to injury as 
well as promote the production of additional inflammatory cytokines. Notably, it is well 
documented that leptin is mainly produced and secreted by adipocytes in direct 
proportion to adipose mass46, 199. Hence, as the perivascular adipose mass increases 
with obesity132-134, leptin may function as a ―feed forward‖ initiator of vascular dysfunction 
leading ultimately to disease (Figure 5-5). This hypothesis is supported by experiments 
demonstrating that leptin has 4 to 5-fold increase in gene expression at the onset of an 
atherogenic diet and before the development of an advanced atherosclerotic lesion206. 
Moreover, MCP-1 (and potentially other chemokines) stimulates the further secretion of 
leptin44.      
 
Figure 5-5 Proposed “feed forward” disease mechanism of perivascular adipose-
derived leptin. Results from this work suggest that perivascular adipose-derived leptin 
exacerbates coronary endothelial dysfunction through PKC-β. Previous studies have 
also shown leptin to be a potent monocyte chemoattractant197. Hence, as perivascular 
adipose mass increases with obesity a feed forward disease process involving increased 
leptin production begins. Therefore, leptin directly impairs endothelial function and 
initiates a local inflammatory response that may further damage the coronary artery.    
 
 
93 
 
Future Directions & Proposed Studies  
 Findings from this body of work are numerous; however, several key issues need 
to be addressed in future studies. In particular, several questions surround the signaling 
cascade of leptin, the functional contribution of coronary vasa vasorum, and the link 
between leptin and adiponectin activity. Together, these proposed issues would help to 
advance our understanding of how perivascular adipose-derived adipokines contribute to 
coronary artery disease.    
Leptin Signal Transduction 
Future studies need to further characterize the link between leptin and eNOS 
activity. While findings from this work strongly implicate leptin to be a critical paracrine 
regulator of endothelial dysfunction, additional molecular studies with leptin and eNOS 
would provide further experimental evidence. Specifically, western blot ―proof of 
principle‖ experiments similar to those illustrated in Chapter 3194 would help demonstrate 
that leptin administration increases site-specific phosphorylation of eNOS at Thr495. In 
addition, NO measurement studies in the presence of exogenous leptin and/or 
ruboxistaurin could further demonstrate the attenuating influence of leptin on NO 
production. Results from these experiments could unequivocally link endothelial leptin 
signaling with PKC-β mediated decreases in eNOS activity. 
Subsequent experiments also need to elucidate the signaling cascade linking 
leptin and endothelial PKC activity. Unfortunately, the complexity of leptin signaling will 
make elucidating an unambiguous mechanism between leptin and PKC difficult. 
Particularly, leptin is associated with the JAK (Janus kinases)/STAT (signal transducers 
and activators of transcription), PI3K, and MAPK (mitogen-activated protein kinase) 
signaling cascades199. While leptin signaling remains poorly understood, repeating some 
in vitro isometric tension studies with lean Ossabaw swine arteries in the presence of 
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various inhibitors could quickly address the functional contribution of several kinases to 
the leptin signaling cascade. In particular, previous results suggest that inhibition of PI3K 
or phospholipase C (PLC) may effectively block leptin-induced endothelial dysfunction 
(Figure 5-4)199, 205.  
 Previous investigations have also documented that leptin is functionally similar to 
monocyte chemoattractant-1 (MCP-1)197. A study from Gruen et al observed that leptin 
receptors (OB-Rb) present on macrophages increase cellular motility to the same 
degree as MCP-1. These findings support our proposal that leptin is a ―feed forward‖ 
initiator of vascular dysfunction (Figure 5-5). Future immunohistochemistry studies could 
provide experimental evidence of leptin functioning as a perivascular chemoattractant. 
Notably, experiments desgined to co-localize perivascular adipose leptin with 
macrophage infiltration may provide correlative evidence of leptin-induced monocyte 
infiltration.  
  Lastly, several investigations have described adiponectin as an anti-inflammatory 
adipokine that is commonly decreased in the setting of obesity42. Importantly, a recent 
clinical study documented that perivascular adipose volume and hypoadipnectinemia are 
the strongest indicators of coronary atherosclerosis116. Several other investigators have 
suggested that adiponectin may attenuate the effect of leptin and other inflammatory 
adipokines 41, 42, 44, 46, 58.  
In consideration of these clinical findings, future experiments should investigate if 
hypoadiponectinemia directly contributes to the disease causing activity of 
hyperleptinemia. A study from Mohler et al illustrates that although adiponectin gene 
expression doubles during the first month of an atherogenic diet, leptin expression 
quadruples and is maintained for three to four months206. One potential experimental 
design includes using genetically engineered rodent models to overexpress adiponectin 
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and/or leptin. In addition, lentiviral vector overexpression of adiponectin in the 
perivascular adipose tissue of MetS swine offers a unique experimental approach that 
could show functional benefit in a large animal model of cardiovascular disease (Figure 
5-6).       
Vasa Vasorum: “Is there really a direct link” 
The most noticeable uncertainty regarding our proposed mechanism is 
discerning whether perivascular adipose-derived factors are capable of traveling to the 
vascular wall and affecting the endothelium. While experimental evidence has 
demonstrated that increased coronary vasa vasorum neovascularization precedes overt 
coronary endothelial dysfunction and disease120, no study has clearly demonstrated if 
vasa vasorum contribute to disease.  Future studies should focus on developing 
experimental evidence that perivascular adipose-derived leptin contributes directly to 
disease. As Figure 5-6 illustrates, experimental techniques exist that could selectively 
over-express leptin in the coronary epicardial adipose tissue. This use of a lentiviral 
vector containing leptin would be an interesting ―proof of principle‖ experimental 
approach to address this critical concern.   
 
Figure 5-6 Lentiviral transduction incubation of Ossabaw coronary arteries. 
Representative picture demonstrating in vitro lentiviral GFP (green) transduction of 
perivascular adipose tissue and left circumflex coronary artery (images of endothelial 
and adventitial surface, A). Confocal image of GFP expression in perivascular adipose 
tissue following in vitro lentiviral injection.  
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      In addition to leptin overexpression, future investigations could also attempt 
characterize a relationship between perivascular adipose growth, increased adipokine 
production, and increased vasa vasorum density. Specifically, it is important to address 
whether a particular cytokine and/or cellular event triggers the angiogenic response of 
vasa vasorum. Experiments monitoring the growth of perivascular adipose tissue and 
development of vasa vasorum density at various time points would permit investigators 
to correlate adipokine expression with various stages of disease.  
Notably, hypoxia and/or vascular endothelial growth factor (VEGF) have both 
been associated with adipose growth207. Futhermore, VEGF and leptin genes are both 
hypoxia inducible, but potential links between VEGF and leptin gene expression have 
not been examined207. Together, vascular hypoxia, VEGF, and leptin may serve as an 
important link between perivascular adipose-induced dysfunction and vasa vasorum 
trafficking.         
Identification of other perivascular adipose-derived agents 
Finally, it is unlikely that leptin is solely responsible for perivascular adipose-
induced endothelial dysfunction. Therefore, proteomic analysis of perivascular adipose 
tissue or conditioned buffer would likely help identify other mediating agents derived 
from perivascular adipose tissue. Employment of a multiplexed biomarker assay and 
targeted proteomics could enable future investigations to identify both known and 
unknown proteins that have significantly elevated perivascular adipose expression. In 
order to find functional significance, perivascular adipose-conditioned buffers could be 
prepared, fractioned by molecular weight, and systematically tested for any affect on 
vascular reactivity. Leptin receptor deficient rodents could also represent a unique 
opportunity to test the effect of perivascular adipose independent of leptin activity. 
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Clinical Implications 
Since obesity-associated coronary artery disease is a leading cause of death and 
morbidity, implications from these investigations stand to substantially increase the 
clinical importance of epicardial adipose tissue. Increased perivascular adipose tissue 
surrounding conduit coronary arteries could be a new and potentially powerful diagnostic 
tool for predicting coronary atherosclerosis116. Diagnostic imaging and quantification of 
perivascular adipose volume, therefore, should be considered as a diagnostic indicator 
for patients who are particularly at risk of myocardial infarction. In addition, our 
observations underscore the clinical value of measuring leptin and other inflammatory 
adipokines in order to develop a personalized ―pro-atherosclerotic‖ profile for each at risk 
patient. These imaging techniques would be most applicable to the general at risk 
population, given the relative difficulty (and unwarranted harm) of directly measuring 
perivascular adipose expression. However, direct sampling and measurement of 
epicardial adipokine production following coronary artery bypass graft procedures 
potentially represents an effective determinant of when (and where) vascular disease 
may reoccur. 
Findings from these investigations also suggest that preemptive blockade of 
PKC-β may help to ameliorate endothelial function and prevent early stages of vascular 
disease. With the incredibly rise of childhood obesity, therapies directed towards 
blocking the development of cardiovascular disease are more important than ever. Early 
therapeutic targeting of PKC-β may provide beneficial health outcomes, and decrease 
the severity/onset of vascular disease.    
 Lastly, perivascular adipose may also contribute to the pathogenesis of other 
obesity-associated cardiovascular diseases. Notably, hypertension has been associated 
with endothelial dysfunction208. The current findings suggest that local perivascular 
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adipose surrounding other vascular networks may contribute to endothelial dysfunction 
and potentially hypertension40. Given our observations and the proposed link between 
leptin and hypertension209, 210, perivascular adipose tissue appears to be conveniently 
positioned to influence vascular resistance and local blood pressure regulation.          
Concluding Remarks 
 Despite the growing obesity epidemic, the pathophysiologic mechanisms 
underlying the link between obesity and cardiovascular disease remain poorly 
understood. Obesity and MetS are associated with endothelial dysfunction, which is 
proposed to initiate coronary artery disease.  The central goal of the previous studies 
was to demonstrate that local perivascular adipose tissue was a significant regulator of 
coronary vascular function and contributor to the development of coronary artery 
disease. Results from these investigations clearly illustrate that perivascular adipose-
derived factors impair coronary endothelial function through direct inhibition of NO 
synthase. This impairment was mediated via a PKC-β dependent, site-specific 
phosphorylation of eNOS at Thr495. Importantly, perivascular adipose-derived leptin 
markedly exacerbated endothelial dysfunction through a PKC-β dependent mechanism 
in the setting of MetS. These investigations are among the first to characterize a specific 
mechanism linking perivascular adipose with vascular disease. Above all, the present 
findings suggest that perivascular adipose tissue contributes to coronary disease, and 
highlight the potential diagnostic benefit of monitoring epicardial adipose growth and 
expression.       
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